[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 574
1. Sells DM, Brix AE, Nyska A, Jokinen MP, Orzech DP, Walker NJ: Respiratory tract lesions in noninhalation studies. Toxicol Pathol; 2007 Jan;35(1):170-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes included respiratory epithelial hyperplasia, degeneration and necrosis of olfactory epithelium, olfactory epithelial metaplasia, adenoma, adenocarcinoma, squamous cell carcinoma, and neuroblastoma.
  • In the lung, compound-related lesions included alveolar histiocytosis, alveolar epithelial hyperplasia, bronchiolar metaplasia of the alveolar epithelium, squamous metaplasia, alveolar/bronchial adenoma and carcinoma, and squamous tumors.
  • [MeSH-minor] Administration, Oral. Injections. Lung / drug effects. Nasal Cavity / drug effects. Nasal Cavity / pathology. Nasal Mucosa / drug effects. Nasal Mucosa / pathology. Toxicity Tests / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gan. 1979 Feb;70(1):29-36 [446975.001]
  • [Cites] Toxicol Pathol. 2005;33(3):371-7 [15805076.001]
  • [Cites] Anticancer Res. 1981;1(5):279-86 [7345971.001]
  • [Cites] Cancer Res. 1982 Oct;42(10):4236-40 [7105017.001]
  • [Cites] Environ Health Perspect. 1990 Apr;85:177-86 [2200661.001]
  • [Cites] Environ Health Perspect. 1990 Apr;85:275-89 [2200667.001]
  • [Cites] Arch Toxicol. 1991;65(1):1-9 [2043044.001]
  • [Cites] Toxicol Pathol. 1991;19(4 Pt 1):321-36 [1813979.001]
  • [Cites] J Toxicol Environ Health A. 2002 Apr 12;65(7):523-37 [11939710.001]
  • [Cites] Toxicol Pathol. 2002 Mar-Apr;30(2):178-87 [11950161.001]
  • [Cites] Arch Toxicol. 2003 Apr;77(4):233-42 [12698239.001]
  • [Cites] Toxicol Pathol. 2004 May-Jun;32(3):333-7 [15204975.001]
  • [Cites] Toxicol Pathol. 1991;19(4 Pt 1):358-72 [1813982.001]
  • [Cites] Drug Metab Dispos. 1992 Sep-Oct;20(5):643-52 [1358567.001]
  • [Cites] Drug Metab Rev. 1993;25(1-2):173-205 [8449146.001]
  • [Cites] J Histochem Cytochem. 1993 Jun;41(6):877-85 [8315279.001]
  • [Cites] Biochem Pharmacol. 1995 May 17;49(10):1387-94 [7763281.001]
  • [Cites] Toxicol Pathol. 1996 Sep-Oct;24(5):564-72 [8923677.001]
  • [Cites] Cancer Res. 1980 Feb;40(2):298-302 [7356512.001]
  • (PMID = 17325986.001).
  • [ISSN] 0192-6233
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 ES999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Xenobiotics
  • [Number-of-references] 24
  • [Other-IDs] NLM/ NIHMS33525; NLM/ PMC3433271
  •  go-up   go-down


2. McGlothlin JR, Gao L, Lavoie T, Simon BA, Easley RB, Ma SF, Rumala BB, Garcia JG, Ye SQ: Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor. Biochem Genet; 2005 Apr;43(3-4):127-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During our previous attempt to search for the candidate genes to acute lung injury (ALI), we unexpectedly identified PBEF as the most highly upregulated gene in a canine model of ALI by crosshybridizing canine lung cRNA to the Affymetrix human gene chip HG-U133A.
  • Canine PBEF protein was successfully expressed both by in vitro transcription coupled with translation in a cell-free system and by transfection of canine PBEF cDNA into the human lung type II alveolar adenocarcinoma cell line A549.
  • RT-PCR assay indicates that canine PBEF is expressed in canine lung, brain, heart, liver, spleen, kidney, pancreas, and muscle, with liver showing the highest expression,followed by muscle.
  • [MeSH-minor] Amino Acid Sequence. Animals. Biomarkers. Cell Line. Cloning, Molecular. Dogs. Endothelium, Vascular / cytology. Gene Expression. Humans. Lung. Male. Mice. Molecular Sequence Data. Nicotinamide Phosphoribosyltransferase. Rats. Recombinant Proteins / biosynthesis. Respiratory Distress Syndrome, Adult / diagnosis. Respiratory Distress Syndrome, Adult / genetics. Sequence Alignment. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15934174.001).
  • [ISSN] 0006-2928
  • [Journal-full-title] Biochemical genetics
  • [ISO-abbreviation] Biochem. Genet.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL58504; United States / NHLBI NIH HHS / HL / U01HL66583
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytokines; 0 / DNA, Complementary; 0 / Recombinant Proteins; EC 2.4.2.12 / Nicotinamide Phosphoribosyltransferase; EC 2.4.2.12 / nicotinamide phosphoribosyltransferase, human
  •  go-up   go-down


3. Malhotra G, Nair N, Awasare S: F-18 FDG PET scan findings in a case of carcinoma of the breast with a rare site of metastases to the gingival region. Clin Nucl Med; 2006 Dec;31(12):820-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She presented after 2 years with an exophytic growth in the upper alveolar region of the oral cavity.
  • Biopsy indicated gingival metastasis from a poorly differentiated adenocarcinoma of the breast.
  • Whole-body F-18 FDG PET scan showed hypermetabolic foci in the midmaxillary region (SUV max: 6.5), upper end of the right humerus, a large hypermetabolic area in the upper zone of the right lung with contiguous hilar node involvement on the right side of the lung, and an area of intense hypermetabolic activity in the left acetabular and ischial region.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Gingival Neoplasms / radionuclide imaging. Gingival Neoplasms / secondary. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117085.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


Advertisement
4. Edey AJ, Hansell DM: Incidentally detected small pulmonary nodules on CT. Clin Radiol; 2009 Sep;64(9):872-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / radiography. Lung Neoplasms / radiography. Multiple Pulmonary Nodules / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Calcinosis / radiography. Diagnosis, Differential. Hamartoma / radiography. Humans. Incidental Findings. Lung. Lymph Nodes / pathology. Lymph Nodes / radiography. Middle Aged. Practice Guidelines as Topic. Radiation Dosage. Reproducibility of Results. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664477.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 78
  •  go-up   go-down


5. Ioachimescu OC, Mehta AC: From cystic pulmonary airway malformation, to bronchioloalveolar carcinoma and adenocarcinoma of the lung. Eur Respir J; 2005 Dec;26(6):1181-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From cystic pulmonary airway malformation, to bronchioloalveolar carcinoma and adenocarcinoma of the lung.
  • The authors present an unusual case of BAC developed in an area of CPAM, with subsequent progression to metastatic adenocarcinoma (AC).
  • The case is unique due to the combination of: early age of presentation; neoplastic transformation of a CPAM; unaltered course over 15 yrs; and its particular pattern of slow morphogenesis and degeneration into an invasive AC of the lung.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Cell Transformation, Neoplastic / pathology. Cystic Adenomatoid Malformation of Lung, Congenital / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16319347.001).
  • [ISSN] 0903-1936
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


6. Hutt JA, Vuillemenot BR, Barr EB, Grimes MJ, Hahn FF, Hobbs CH, March TH, Gigliotti AP, Seilkop SK, Finch GL, Mauderly JL, Belinsky SA: Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways. Carcinogenesis; 2005 Nov;26(11):1999-2009
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways.
  • Although cigarette smoke has been epidemiologically associated with lung cancer in humans for many years, animal models of cigarette smoke-induced lung cancer have been lacking.
  • This study demonstrated that life time whole body exposures of female B6C3F1 mice to mainstream cigarette smoke at 250 mg total particulate matter/m(3) for 6 h per day, 5 days a week induces marked increases in the incidence of focal alveolar hyperplasias, pulmonary adenomas, papillomas and adenocarcinomas.
  • Cigarette smoke-exposed mice (n = 330) had a 10-fold increase in the incidence of hyperplastic lesions, and a 4.6-fold (adenomas and papillomas), 7.25-fold (adenocarcinomas) and 5-fold (metastatic pulmonary adenocarcinomas) increase in primary lung neoplasms compared with sham-exposed mice (n = 326).
  • These results emphasize the importance of the activation of K-ras and silencing of DAP-kinase and RAR-beta in lung cancer development, and confirm the relevance of this mouse model for studying lung tumorigenesis.
  • [MeSH-major] DNA Methylation. Gene Silencing / drug effects. Lung / drug effects. Lung Neoplasms / chemically induced. Lung Neoplasms / genetics. Smoking / adverse effects
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Adenoma / chemically induced. Adenoma / genetics. Adenoma / pathology. Administration, Inhalation. Animals. Apoptosis Regulatory Proteins. Body Weight. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Cell Proliferation / drug effects. Death-Associated Protein Kinases. Female. Genes, ras / drug effects. Hyperplasia / chemically induced. Hyperplasia / genetics. Hyperplasia / pathology. Incidence. Mice. Mice, Inbred Strains. Organ Size. Papilloma / chemically induced. Papilloma / genetics. Papilloma / pathology. Point Mutation. Promoter Regions, Genetic. Pulmonary Alveoli / drug effects. Pulmonary Alveoli / metabolism. Pulmonary Alveoli / pathology. Receptors, Retinoic Acid / genetics. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Carcinogenesis. 2005 Dec;26(12):2214
  • (PMID = 15944214.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES08801; United States / NCRR NIH HHS / RR / RR00136CA
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor beta; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


7. Roch A, Shlyonsky V, Goolaerts A, Mies F, Sariban-Sohraby S: Halothane directly modifies Na+ and K+ channel activities in cultured human alveolar epithelial cells. Mol Pharmacol; 2006 May;69(5):1755-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Halothane directly modifies Na+ and K+ channel activities in cultured human alveolar epithelial cells.
  • During inhalational anesthesia, halogenated gases are in direct contact with the alveolar epithelium, in which they may affect transepithelial ion and fluid transport.
  • The effects of halogenated gases in vivo on epithelial Na+ and K+ channels, which participate in alveolar liquid clearance, remain unclear.
  • In the present study, the effects of halothane (1, 2, and 4% atm) on ion-channel function in cultured human alveolar cells were investigated using the patch-clamp technique.
  • Thus, halothane modifies differentially and independently Na+ and K+ permeabilities in human alveolar cells.
  • [MeSH-minor] Adenocarcinoma. Cell Line, Tumor. Cells, Cultured. Gases. Halogens / pharmacology. Humans. Lung Neoplasms. Membrane Potentials / drug effects. Membrane Potentials / physiology

  • Hazardous Substances Data Bank. 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399849.001).
  • [ISSN] 0026-895X
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gases; 0 / Halogens; 0 / Potassium Channels; 0 / Sodium Channels; UQT9G45D1P / Halothane
  •  go-up   go-down


8. Raz DJ, He B, Rosell R, Jablons DM: Current concepts in bronchioloalveolar carcinoma biology. Clin Cancer Res; 2006 Jun 15;12(12):3698-704
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts in bronchioloalveolar carcinoma biology.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778095.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093708-02; United States / NCI NIH HHS / CA / R01 CA093708; United States / NCI NIH HHS / CA / R01 CA093708-02
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 61
  •  go-up   go-down


9. Goto A, Niki T, Chi-Pin L, Matsubara D, Murakami Y, Funata N, Fukayama M: Loss of TSLC1 expression in lung adenocarcinoma: relationships with histological subtypes, sex and prognostic significance. Cancer Sci; 2005 Aug;96(8):480-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of TSLC1 expression in lung adenocarcinoma: relationships with histological subtypes, sex and prognostic significance.
  • The TSLC1 (tumor suppressor in lung cancer 1) gene is a tumor suppressor recently identified through functional complementation in a lung adenocarcinoma cell line A549.
  • In this study we immunohistochemically examined the loss of TSLC1 expression in 93 cases of surgically resected lung adenocarcinoma, and investigated its correlation with clinicopathological parameters, including histological subtypes of tumors.
  • In non-cancerous lung tissue, TSLC1 was weakly positive in bronchial and bronchiolar epithelial cells, type II pneumocytes and bronchial glands.
  • Overall, TSLC1 was negative in 60 of 93 lung adenocarcinomas.
  • Notably, TSLC1 expression was preserved in a non-invasive, bronchiolo-alveolar histological pattern of tumor cells (P < 0.0001).
  • We conclude that TSLC1 is expressed in a subset of lung adenocarcinomas, especially in those with bronchiolo-alveolar spread pattern.
  • [MeSH-major] Adenocarcinoma / genetics. Immunoglobulins / genetics. Lung Neoplasms / genetics. Membrane Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16108829.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CADM1 protein, human; 0 / Cell Adhesion Molecules; 0 / Immunoglobulins; 0 / Membrane Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


10. Nasrallah SM, Maytal G, Skarf LM: Patient-physician boundaries in palliative care training: a case study and discussion. J Palliat Med; 2009 Dec;12(12):1159-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / psychology. Anxiety. Humans. Lung Neoplasms / pathology. Lung Neoplasms / psychology. Male. Middle Aged. Neoplasm Metastasis


11. Chujo M, Yoshimatsu T, Kimura T, Ito K, Tokunaga Y, Nakamura N, Tanaka H, Ueda S, Uchida Y, Kawahara K: [Pulmonary thromboembolism after thoracoscopic pulmonary wedge resection; report of a case]. Kyobu Geka; 2005 Mar;58(3):243-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We encountered a case of acute pulmonary embolism after lung cancer surgery.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / surgery. Pneumonectomy. Pulmonary Embolism / etiology
  • [MeSH-minor] Acute Disease. Female. Humans. Lung Neoplasms / surgery. Middle Aged. Postoperative Complications. Thoracoscopy

  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776746.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Shinmura K, Suzuki M, Yamada H, Tao H, Goto M, Kamo T, Nagura K, Kageyama S, Kato M, Ogawa S, Maekawa M, Takamochi K, Suzuki K, Nakamura T, Sugimura H: Characterization of adenocarcinoma of the lung in a familial adenomatous polyposis patient. Pathol Int; 2008 Nov;58(11):706-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of adenocarcinoma of the lung in a familial adenomatous polyposis patient.
  • The incidence of several extracolonic tumors, such as duodenal carcinoma, is higher in familial adenomatous polyposis (FAP) patients than in the general population, but there is little information about lung carcinoma in FAP.
  • A 43-year-old woman presented with a lung tumor 17 years after total colectomy for FAP.
  • Pathohistological analysis of the lung tumor demonstrated mixed adenocarcinoma consisting of a papillary adenocarcinoma component and a bronchioloalveolar carcinoma component.
  • The other APC allele in the lung carcinoma was not inactivated by somatic mutations, promoter methylation, or chromosomal deletion.
  • The present results suggest that the chromosomal copy number alterations detected on SNP microarray were involved in the carcinogenesis of the adenocarcinoma of the lung in the present FAP patient.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Papillary / pathology. Adenomatous Polyposis Coli / pathology. Lung Neoplasms / pathology


13. Zielonka TM: [Bronchioloalveolar carcinoma]. Pol Merkur Lekarski; 2005 Feb;18(104):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bronchioloalveolar carcinoma (BALC) is a sub-type of adenocarcinoma, accounting for 3-5% of all lung cancer cases.
  • It is characterized by peripheral location in lung parenchyma, without visible changes in main bronchi and tumor spread occurs along the walls of the peripheral airspaces without destruction of the pulmonary interstitium.
  • It is difficult to provide a correct diagnosis.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Lung Neoplasms / diagnosis. Lung Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Age Distribution. Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / pathology. Bronchial Neoplasms / surgery. Humans. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Risk Factors. Sex Distribution. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17877136.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 44
  •  go-up   go-down


14. Sholl LM, Yeap BY, Iafrate AJ, Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu J, Loda M, Jänne PA, Christiani DC, Chirieac LR: Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res; 2009 Nov 1;69(21):8341-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.
  • In a subset of lung adenocarcinomas, the epidermal growth factor receptor (EGFR) is activated by kinase domain mutations and/or gene amplification, but the interaction between the two types of abnormalities is complex and unclear.
  • For this study, we selected 99 consecutive never-smoking women of East Asian origin with lung adenocarcinomas that were characterized by histologic subtype.
  • Lung adenocarcinomas with EGFR amplification had significantly more EGFR exon 19 deletion mutations than adenocarcinomas with disomy, and low and high polysomy (100% versus 54%, P = 0.009).
  • EGFR amplification was focally distributed in lung cancer specimens, mostly in regions with solid histology.
  • Lung adenocarcinomas with EGFR amplification have a unique association with exon 19 deletion mutations and show distinct clinicopathologic features associated with a significantly worsened prognosis.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):3023-8 [19366827.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):485-95 [16730237.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2046-53 [17332333.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2248-55 [17538169.001]
  • [Cites] Mod Pathol. 2007 Oct;20(10):1028-35 [17673923.001]
  • [Cites] J Thorac Oncol. 2008 Apr;3(4):340-7 [18379350.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2106-11 [18381415.001]
  • [Cites] J Mol Diagn. 2008 May;10(3):242-8 [18403609.001]
  • [Cites] Am J Surg Pathol. 2008 Jun;32(6):810-27 [18391747.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1367-80 [18815398.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8195-203 [15623594.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):226-35 [15665299.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94 [16106023.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):751-8 [16467085.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Aug;1(3):192-200 [19138956.001]
  • [Cites] PLoS One. 2009;4(2):e4576 [19238210.001]
  • [Cites] Am J Clin Pathol. 2006 Jun;125(6):860-5 [16690485.001]
  • (PMID = 19826035.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / CA092824; United States / NCI NIH HHS / CA / CA074386; United States / NCI NIH HHS / CA / CA090578-01A10003; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / R0I CA114465; United States / NCI NIH HHS / CA / R01 CA114465; United States / NCI NIH HHS / CA / P20 CA090578-01A10003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS143923; NLM/ PMC2783286
  •  go-up   go-down


15. Yano S, Nakataki E, Ohtsuka S, Inayama M, Tomimoto H, Edakuni N, Kakiuchi S, Nishikubo N, Muguruma H, Sone S: Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res; 2005;15(2):107-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.
  • Gefitinib is a selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinases, and shows favorable antitumor activity against chemorefractory non-small cell lung cancer (NSCLC).
  • All three cases were nonsmokers and showed an adenocarcinoma histology.
  • While they had experienced successful control from their initial treatment with gefitinib for more than 12 months, gefitinib therapy was terminated because two cases (cases 1 and 3) relapsed during the therapy and case 2 suffered alveolar hemorrhage.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119008.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


16. Ogata K, Morooka M: [Case of cryptogenic organizing pneumonia with radiologically detectable lung cancer after disappearance of infiltrative shadows by steroid treatment]. Nihon Kokyuki Gakkai Zasshi; 2008 Oct;46(10):853-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of cryptogenic organizing pneumonia with radiologically detectable lung cancer after disappearance of infiltrative shadows by steroid treatment].
  • A chest radiograph demonstrated infiltrative shadows in the bilateral middle and lower lung fields and a chest CT scan showed the shadows in the bilateral upper and lower lobes.
  • After admission, infiltrative shadows in the right upper lobe increased and transbronchial lung biopsy (TBLB) specimens disclosed organizing exudates in the alveolar spaces.
  • Lung adenocarcinoma was diagnosed by TBLB specimens of residual shadows.
  • Few cases of cryptogenic organizing pneumonia (COP) with lung cancer have been reported, and further consideration should be given to the relationship between COP and lung cancer.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / radiography. Cryptogenic Organizing Pneumonia / complications. Cryptogenic Organizing Pneumonia / radiography. Lung Neoplasms / complications. Lung Neoplasms / radiography. Prednisolone / administration & dosage. Tomography, X-Ray Computed


17. Casali C, Rossi G, Marchioni A, Sartori G, Maselli F, Longo L, Tallarico E, Morandi U: A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. J Thorac Oncol; 2010 Jun;5(6):830-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice.
  • METHODS: Retrospective analysis of resected BAC reclassified according to the 2004 World Health Organization classification of lung tumors.
  • Locally advanced nonmucinous BAC has a poor prognosis: the diagnosis of nonmucinous BAC in large tumors should be interpreted with caution given the possible presence of invasive areas in incompletely sampled tumor.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20521350.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


18. Morandi L, Asioli S, Cavazza A, Pession A, Damiani S: Genetic relationship among atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and adenocarcinoma of the lung. Lung Cancer; 2007 Apr;56(1):35-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic relationship among atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and adenocarcinoma of the lung.
  • Atypical adenomatous hyperplasia (AAH) has been recently defined by WHO as a small lesion, not exceeding 5mm in major axis, composed of slightly enlarged alveolar septa lined by pneumocytes with plump, atypical nuclei.
  • AAH is frequently found in tissue surrounding lung adenocarcinoma and is considered a precursor of this subtype of lung cancer by many Authors.
  • However, the genetic relationship between adenocarcinoma and the associated foci of AAH is not well defined.
  • In particular, it is not clear whether multiple foci of AAH and of adenocarcinoma in the same patients are clonally related to each other or represent independent neoplastic foci.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenomatosis, Pulmonary / genetics. Lung Neoplasms / genetics. Precancerous Conditions / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241687.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


19. Laskin JJ, Sandler AB, Johnson DH: Redefining bronchioloalveolar carcinoma. Semin Oncol; 2005 Jun;32(3):329-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bronchioloalveolar carcinoma (BAC) is a subtype of non-small cell lung cancer (NSCLC) with distinct clinical and pathologic features.
  • Although BAC appears to be on a pathologic continuum with adenocarcinoma, the most recent World Health Organization (WHO) classification system has set stringent criteria for the diagnosis.
  • Though malignant, these cancers tend to be peripheral and grow in a lepedic fashion along the alveolar septae without parenchymal invasion.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar. Lung Neoplasms

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15988687.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 49
  •  go-up   go-down


20. Otani S, Sato Y, Endo S, Hasegawa T, Tezuka Y, Endo T, Sohara Y: [Prognosis of patients after resection for lung cancer with intrapulmonary metastasis in different lobes]. Kyobu Geka; 2006 Jan;59(1):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis of patients after resection for lung cancer with intrapulmonary metastasis in different lobes].
  • BACKGROUND: The prognosis of lung cancer patients with intrapulmonary metastasis in different lobes (pm2) is poor.
  • We retrospectively investigated the prognosis of resected primary lung cancer patients with pm2.
  • METHOD: Among 845 patients with primary lung cancer who underwent complete resection from 1984 to 2003, 14 cases that had lung cancer with pm2 were evaluated about prognostic factors.
  • CONCLUSION: Lung cancer patients with pm2 whose lesions show BAC histology, the absence of pleural invasion or pleural dissemination may achieve long-term survival and could be candidates for surgical treatment.
  • [MeSH-major] Lung / pathology. Lung Neoplasms / pathology. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440681.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Sheikh HA, Sasatomi E, Finkelstein S, Yousem SA: Comparative mutational analysis of pulmonary scar epithelium, bronchioloalveolar carcinomas, and invasive well-differentiated pulmonary adenocarcinomas: a molecular approach to diagnostically challenging cases. Am J Surg Pathol; 2005 Oct;29(10):1267-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Discrimination of invasive well-differentiated adenocarcinoma (IAD) from reactive bronchioloalveolar epithelium entrapped in pulmonary scars (PSE) may be difficult on routine histology, especially on small biopsies.
  • These molecular differences may serve as an adjunct to histology in challenging glandular lesions of the lung.
  • [MeSH-major] Cicatrix / genetics. DNA, Neoplasm / analysis. Lung Diseases / genetics. Lung Neoplasms / genetics. Respiratory Mucosa / pathology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / pathology. DNA Mutational Analysis. Diagnosis, Differential. Genes, Tumor Suppressor / physiology. Humans. Loss of Heterozygosity. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Scars.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160467.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


22. Suzuki C, Daigo Y, Ishikawa N, Kato T, Hayama S, Ito T, Tsuchiya E, Nakamura Y: ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res; 2005 Dec 15;65(24):11314-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway.
  • Gene expression profile analysis of non-small cell lung cancers (NSCLC) and subsequent functional analyses revealed that human ANLN, a homologue of anillin, an actin-binding protein in Drosophila, was transactivated in lung cancer cells and seemed to play a significant role in pulmonary carcinogenesis.
  • Immunohistochemical staining of nuclear ANLN on lung cancer tissue microarrays was associated with the poor survival of NSCLC patients, indicating that this molecule might serve as a prognostic indicator.
  • Our data imply that up-regulation of ANLN is a common feature of the carcinogenetic process in lung tissue, and suggests that selective suppression of ANLN could be a promising approach for developing a new strategy to treat lung cancers.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Contractile Proteins / metabolism. Lung Neoplasms / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. rhoA GTP-Binding Protein / metabolism
  • [MeSH-minor] Actins / metabolism. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Blotting, Western. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Movement. Enzyme Activation. Female. Flow Cytometry. Humans. Lung / metabolism. Lung / pathology. Male. Middle Aged. Prognosis. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Survival Rate. Tissue Array Analysis. Tumor Cells, Cultured. Wound Healing

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357138.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Contractile Proteins; 0 / RNA, Small Interfering; 0 / anillin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


23. Saad RS, Liu YL, Silverman JF: Distribution of basal/myoepithelial markers in benign and malignant bronchioloalveolar proliferations of the lung. Appl Immunohistochem Mol Morphol; 2010 May;18(3):219-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of basal/myoepithelial markers in benign and malignant bronchioloalveolar proliferations of the lung.
  • We investigated the staining pattern of commonly used basal cell/myoepithelial markers, such as p63 (a p53-homologous nuclear protein), basal cell-specific cytokeratin antibody (34betaE12, K903), and smooth muscle myosin heavy chain (SMMHC) in benign and malignant bronchioloalveolar proliferations of the lung.
  • We studied 85 lung lesions consisting of 35 bronchioloalveolar carcinoma, 30 well-differentiated adenocarcinoma, and 20 cases of benign lung lesions.
  • In normal lung, p63, K903, and SMMHC decorated the basal cells of large and small airways and occasional cells of terminal bronchioles.
  • Respiratory ciliated cells, alveolar epithelial cells, and nonepithelial cells were negative.
  • For adenocarcinoma, a majority of the cases (28/30, 93%) were negative for p63 and K903; however, SMMHC showed artifactual staining in the desmoplastic stroma in 6/30 (20%) cases.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065853.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 3.6.1.- / Smooth Muscle Myosins
  •  go-up   go-down


24. Quoix E: [Recent development of the standards of treatment of lung cancer]. Rev Prat; 2007 Feb 15;57(3):239-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recent development of the standards of treatment of lung cancer].
  • Non-small cell lung cancer (NSCLC) knows important changes with the development of the use of chemotherapy not only in the advanced forms but also in a perioperative setting.
  • Targeted therapies have been the real novelty in the treatment of non-small cell lung cancer.
  • Regarding small-cell lung cancer, there has been no real novelty, the standard treatment remains unchanged.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Neoadjuvant Therapy
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / surgery. Carcinoma, Small Cell / surgery. Chemotherapy, Adjuvant. Humans. Pneumonectomy. Radiotherapy, Adjuvant


25. Loreto C, Carnazza ML, Cardile V, Libra M, Lombardo L, Malaponte G, Martinez G, Musumeci G, Papa V, Cocco L: Mineral fiber-mediated activation of phosphoinositide-specific phospholipase c in human bronchoalveolar carcinoma-derived alveolar epithelial A549 cells. Int J Oncol; 2009 Feb;34(2):371-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mineral fiber-mediated activation of phosphoinositide-specific phospholipase c in human bronchoalveolar carcinoma-derived alveolar epithelial A549 cells.
  • Given the role of phosphoinositide-specific phospholipase C (PLC) isozymes in the control of cell growth and differentiation we were prompted to analyze the expression of some of these PLC in human bronchoalveolar carcinoma-derived alveolar epithelial A549 cells.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Asbestos, Crocidolite / toxicity. Lung Neoplasms / pathology. Phospholipase C beta / metabolism. Phospholipase C delta / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TREMOLITE ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148471.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Asbestos, Amphibole; 0 / Phosphatidylinositols; 12001-28-4 / Asbestos, Crocidolite; 14567-73-8 / tremolite; EC 3.1.4.11 / Phospholipase C beta; EC 3.1.4.11 / Phospholipase C delta
  •  go-up   go-down


26. Castaño Z, Vergara-Irigaray N, Pajares MJ, Montuenga LM, Pio R: Expression of alpha CP-4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells. Int J Cancer; 2008 Apr 1;122(7):1512-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of alpha CP-4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells.
  • The protein alpha CP-4 (also known as hnRNP E4) is an RNA binding protein encoded by a gene at 3p21, one of the most common altered regions in lung cancer.
  • It has been proposed that alpha CP-4 may function as a lung tumor suppressor.
  • Lack of alpha CP-4 expression is frequent in highly proliferative lung tumors and correlates with alpha CP-4 allele losses.
  • The aim of this study was to evaluate the effect of alpha CP-4 on the tumorigenic capacity of lung cancer cells. alpha CP-4 expression was induced by transient transfection or stable infection with recombinant retroviruses.
  • Induction of alpha CP-4 expression caused cell cycle arrest in G(2)/M in 3 out of the 7 lung cancer cell lines studied, while no effect on apoptosis was observed.
  • In conclusion, expression of alpha CP-4 can inhibit proliferation and tumorigenesis of lung cancer cells, both in vivo and in vitro, by delaying the progression of the cell cycle.
  • [MeSH-major] Apoptosis. Carcinoma, Non-Small-Cell Lung / metabolism. Cell Cycle. DNA Damage. Lung Neoplasms / metabolism. RNA-Binding Proteins / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Animals. Blotting, Western. Carcinoid Tumor / metabolism. Carcinoma, Large Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Chromosomes, Human, Pair 3. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Mice. Mice, Nude. Retroviridae. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17973258.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PCBP4 protein, human; 0 / RNA-Binding Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


27. Riquet M, Foucault C, Berna P, Assouad J, Dujon A, Danel C: Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg; 2006 Jun;81(6):1988-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping.
  • BACKGROUND: Adenocarcinoma (AC) is the most common lung cancer, followed by squamous cell carcinoma (SCC).
  • Therefore, we compared subgroups according to presence or not of bronchioloalveolar carcinoma or solid adenocarcinoma with mucin component, or both.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adenocarcinoma, Bronchiolo-Alveolar / therapy. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / therapy. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / statistics & numerical data. Combined Modality Therapy. Female. Humans. Life Tables. Male. Middle Aged. Neoplasm Staging. Pneumonectomy / methods. Pneumonectomy / statistics & numerical data. Prognosis. Radiotherapy, Adjuvant / statistics & numerical data. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731118.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Yu JH, Wei Q, Qi FJ, Xu HT, Wang EH: [Significance of caveolin-1 expression in primary lung cancer]. Zhonghua Bing Li Xue Za Zhi; 2006 Nov;35(11):664-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of caveolin-1 expression in primary lung cancer].
  • OBJECTIVE: To study the expression of caveolin-1 in primary lung cancer and its relationship with microvessel density and clinicopathologic parameters.
  • METHODS: Immunohistochemical study for caveolin-1 and CD34 was performed on paraffin sections of 154 cases of primary lung cancer and adjacent non-neoplastic lung parenchymal tissue, as well as 36 cases with nodal metastasis.
  • Western blot assay was also employed in tumor and non-neoplastic lung tissues of the 50 cases (25 cases of pulmonary squamous cell carcinoma and 25 cases of pulmonary adenocarcinoma) with fresh specimens available.
  • RESULTS: Immunohistochemical study showed that non-neoplastic bronchial and alveolar epithelium was positive for caveolin-1 (membranous and cytoplasmic).
  • The expression rate of caveolin-1 in lung cancer was 59.1%, which was significantly lower than that in normal lung tissues (P < 0.01).
  • Western blot assay confirmed that the expression of caveolin-1 in pulmonary squamous cell carcinoma and adenocarcinoma was lower than in surrounding non-neoplastic lung tissues (P < 0.01).
  • CONCLUSIONS: The expression of caveolin-1 is lower in lung cancer tissues than that in non-small cell carcinoma, it is also significantly correlated with tumor stage and lymph node metastasis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Caveolin 1 / biosynthesis. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Blotting, Western. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Humans. Immunohistochemistry. Lung / chemistry. Lung / metabolism. Lung / pathology. Lymphatic Metastasis. Male. Microvessels / chemistry. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Neoplasm Staging. Small Cell Lung Carcinoma / metabolism. Small Cell Lung Carcinoma / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374210.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Caveolin 1
  •  go-up   go-down


29. Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M, Heigener D: Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol; 2010 Oct;5(10):1616-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
  • INTRODUCTION: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor tyrosine-kinase activity that has been shown to significantly increase survival for patients with previously treated advanced non-small cell lung cancer.
  • Here, we report safety and efficacy data from a large, global, open-label, phase IV trial of erlotinib (Tarceva Lung Cancer Survival Treatment).
  • CONCLUSIONS: These data confirm the favorable efficacy and safety profile of erlotinib in a large heterogeneous non-small cell lung cancer population.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Carcinoma, Large Cell / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Erlotinib Hydrochloride. Female. Follow-Up Studies. Humans. International Agencies. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / pathology. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Protein Kinase Inhibitors / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Safety. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736854.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


30. Nakamura N, Kobayashi K, Nakamoto M, Kohno T, Sasaki H, Matsuno Y, Yokota J: Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma. Oncogene; 2006 Jul 13;25(30):4245-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma.
  • To identify tumor markers and differentiation markers for lung adenocarcinoma (AdC), we analysed expression profiles of 14,500 genes against three cases of type II alveolar epithelial cells, bronchiolar epithelial cells, and bronchial epithelial cells, respectively, and 10 cases of AdC cells isolated by laser capture microdissection.
  • Hierarchical clustering analysis indicated that AdC cells and noncancerous lung epithelial cells are significantly different in their expression profiles, and that different sets of differentiation markers are expressed among alveolar, bronchiolar and bronchial epithelial cells.
  • Nine genes were identified as being highly expressed in AdC cells, but not expressed in noncancerous lung epithelial cells.
  • Sixteen genes were identified as differentiation markers for lung epithelial cells.
  • Real-time RT-PCR analysis of 45 lung AdC cases further revealed that expression of four tumor markers in AdC cells was significantly higher than that in noncancerous lung cells and that expression of ten differentiation markers was retained in a considerable fraction of lung AdC cases.
  • Similarities and differences in expression profiles between normal epithelial cells from different lung respiratory compartments and AdC cells demonstrated in this study will be informative for the molecular diagnosis of lung AdC.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Biomarkers, Tumor. Cell Differentiation. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16491115.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


31. Dominguez-Ventura A, Cassivi SD, Allen MS, Wigle DA, Nichols FC, Pairolero PC, Deschamps C: Lung cancer in octogenarians: factors affecting long-term survival following resection. Eur J Cardiothorac Surg; 2007 Aug;32(2):370-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer in octogenarians: factors affecting long-term survival following resection.
  • OBJECTIVE: To identify factors associated with long-term survival following pulmonary resection for lung cancer in patients 80 years of age or older.
  • METHODS: The medical records of all patients >or=80 years, who underwent pulmonary resection for lung cancer from 1985 to 2002, were reviewed.
  • CONCLUSIONS: Meaningful long-term survival is obtainable in elderly patients undergoing surgical resection for lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung / surgery. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Aged, 80 and over. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Neoplasm Staging. Pulmonary Surgical Procedures / methods. Survival Analysis. Time Factors. Treatment Outcome


32. Matsuoka T, Sugi K, Matsuda E, Okabe K, Hirazawa K, Azuma T: [Mycobacterium avium complex (MAC) infection needed differential diagnosis of the recurrence after surgery for double lung cancer; report of a case]. Kyobu Geka; 2007 Dec;60(13):1200-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mycobacterium avium complex (MAC) infection needed differential diagnosis of the recurrence after surgery for double lung cancer; report of a case].
  • A 62-year-old woman had undergone video-assisted thoracic surgery (VATS) -right upper lobectomy and right S8 segmentectomy for double lung cancers (papillary adenocarcinoma and bronchioloalveoler carcinoma, stage IA).
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / surgery. Lung Neoplasms / diagnosis. Lung Neoplasms / surgery. Mycobacterium avium-intracellulare Infection / diagnosis. Neoplasms, Multiple Primary. Tuberculosis, Pulmonary / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Mycobacterium Avium Complex.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18078091.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Ishikawa N, Kohno N: [Interstitial lung disease and lung cancer]. Gan To Kagaku Ryoho; 2010 Jan;37(1):6-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interstitial lung disease and lung cancer].
  • Interstitial lung diseases (ILDs) include more than 200 disease entities such as drug induced ILD, radiation pneumonitis, collagen vascular disease-associated interstitial pneumonia, and idiopathic interstitial pneumonias (IIPs).
  • Idiopathic pulmonary fibrosis (IPF) represents the most common IIP, and is one of the most aggressive interstitial lung diseases.
  • ILDs, especially in IPF, are associated with an independent increased risk of lung cancer.
  • Repetitive stimulation, alveolar epithelial injury and dysregulated repair induced by IPF cause genetic errors, which in turn may predispose to the development of lung cancer.
  • We previously established a mouse IgG1 mAb that recognizes a sialylated sugar chain on lung adenocarcinoma cells, designated KL-6.
  • KL-6 is a high-molecular-weight glycoprotein classified as Cluster 9 (MUC1) lung tumor and differentiation antigens.
  • We also found that there is a natural auto-antibody against KL-6 at high levels in sera from healthy volunteers and at low levels in sera from patients with non-small cell lung cancer.
  • The pathogenesis of lung cancer in ILDs is unclear, but some genetic factors seem to be involved.
  • Further studies are needed to clarify the causes and the mechanisms that link ILDs and lung cancer.
  • [MeSH-major] Lung Diseases, Interstitial / complications. Lung Neoplasms / complications


34. Awab A, Hamadani M, Peyton M, Brown B: False-negative PET scan with bronchioloalveolar carcinoma: an important diagnostic caveat. Am J Med Sci; 2007 Oct;334(4):311-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Positron emission tomography (PET) is becoming widely accepted as a powerful diagnostic tool for the diagnosis of lung cancer, but it has very poor sensitivity for the detection of bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC pattern, the less common form of pulmonary neoplasia.
  • PET has a reported sensitivity of over 98% in most series but misses almost two-thirds of BAC lesions, which might delay invasive testing and early diagnosis of this potentially lethal cancer.
  • Although this diagnostic limitation has been well reported in the radiology literature, the high reported sensitivity and sensitivity can give clinicians a false sense of security with negative PET scans of lung nodules.
  • The usual risk factors for bronchogenic carcinoma are less reliable for these subtypes of non-small-cell lung cancer; thus, clinicians need to have a high index of suspicion for BAC and exercise caution when making decisions on the basis of PET.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / radionuclide imaging. Lung Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030191.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Siddaraju N, Yedlapati GK, Talukdar T, Saka VK, Padmavathy F, Basu D: Cytodiagnostic aspects of bronchioloalveolar carcinoma manifesting with small cell morphology on respiratory specimens: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):1018-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Sputum / cytology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053590.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. De Flora S, Izzotti A, D'Agostini F, Bennicelli C, You M, Lubet RA, Balansky RM: Induction and modulation of lung tumors: genomic and transcriptional alterations in cigarette smoke-exposed mice. Exp Lung Res; 2005 Jan-Feb;31(1):19-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction and modulation of lung tumors: genomic and transcriptional alterations in cigarette smoke-exposed mice.
  • Cigarette smoke plays a major role in the epidemiology of lung cancer, and smoke components have extensively been investigated in carcinogenicity and chemoprevention studies in experimental animals.
  • The authors review here some results obtained in their laboratories, dealing with the induction of lung tumors, and genomic and transciptional alterations in smoke-exposed mice.
  • The authors were successful in inducing lung tumors in 4 strains of mice exposed whole-body to environmental cigarette smoke, including Swiss albino, A/J, SKH-1 hairless, and p53 mutant (UL533 x A/J)F1 mice.
  • Much more intense were the smoke-induced alterations of a variety of intermediate biomarkers, such as cytogenetic end points in pulmonary alveolar macrophages, bone marrow and peripheral blood erythrocytes; apoptosis, p53 oncoprotein, and proliferating cell nuclear antigen in the bronchial epithelium; bulky DNA adducts, 8-hydroxy-2-deoxyguanosine; multigene expression, and thiobarbituric acid-reactive aldehydes in whole lung and several other organs.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinogens / adverse effects. Chemoprevention. Lung Neoplasms / etiology. Tobacco Smoke Pollution / adverse effects. Transcription, Genetic / drug effects
  • [MeSH-minor] Acetylcysteine / therapeutic use. Animals. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Biomarkers. Disease Models, Animal. Drug Antagonism. Gene Expression Profiling. Inhalation Exposure. Macrophages, Alveolar / drug effects. Macrophages, Alveolar / pathology. Mice. Mice, Nude. Micronuclei, Chromosome-Defective / drug effects. Micronucleus Tests. Species Specificity. Sulindac / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Secondhand Smoke.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15765917.001).
  • [ISSN] 0190-2148
  • [Journal-full-title] Experimental lung research
  • [ISO-abbreviation] Exp. Lung Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-05122; United States / NCI NIH HHS / CN / N01-CN-75008
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Biomarkers; 0 / Carcinogens; 0 / Tobacco Smoke Pollution; 184SNS8VUH / Sulindac; WYQ7N0BPYC / Acetylcysteine
  •  go-up   go-down


37. Patsios D, Roberts HC, Paul NS, Chung T, Herman SJ, Pereira A, Weisbrod G: Pictorial review of the many faces of bronchioloalveolar cell carcinoma. Br J Radiol; 2007 Dec;80(960):1015-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bronchioloalveolar cell carcinoma (BAC) has a varied appearance on CT that often leads to an incorrect or delayed diagnosis.
  • These features should alert the radiologist to the diagnosis of BAC.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / radiography. Lung Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940131.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 27
  •  go-up   go-down


38. Dertsiz L, Ozbilim G, Kayisli Y, Gokhan GA, Demircan A, Kayisli UA: Differential expression of VASP in normal lung tissue and lung adenocarcinomas. Thorax; 2005 Jul;60(7):576-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of VASP in normal lung tissue and lung adenocarcinomas.
  • We hypothesise that an increase in the expression of VASP is involved in the progression and invasion of lung adenocarcinomas in parallel to tumour progression.
  • A study was undertaken to analyse VASP expression in normal lung tissue and lung adenocarcinomas.
  • METHODS: Human lung tissues with adenocarcinomas (n = 26) were used.
  • Normal lung tissue specimens (n = 14) were taken from areas a standard distance (3 cm) from resected adenocarcinomas of patients who underwent surgical lung resection.
  • RESULTS: Normal lung pneumocytes showed no VASP expression while alveolar macrophages had the strongest immunoreactivity for VASP.
  • CONCLUSIONS: The spatial and differential expression of VASP in normal lung tissue and lung adenocarcinomas suggests that it is likely to be involved in the differentiation of normal lung cells to adenocarcinomas.
  • The significant increase in the expression of VASP in adenocarcinomas in parallel to pathological staging suggests that it may regulate the invasive behaviour of lung adenocarcinomas as adenocarcinoma invasion is increased in more advanced tumours.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Adhesion Molecules / metabolism. Lung / metabolism. Lung Neoplasms / metabolism. Phosphoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jun 23;101(7):685-8 [10892738.001]
  • [Cites] Ann Thorac Surg. 2005 Mar;79(3):974-9; discussion 979 [15734416.001]
  • [Cites] J Clin Pathol. 2001 Jul;54(7):498-9 [11429418.001]
  • [Cites] Mol Hum Reprod. 2002 Jan;8(1):88-94 [11756574.001]
  • [Cites] Mol Hum Reprod. 2002 Nov;8(11):1023-30 [12397215.001]
  • [Cites] Chest. 2003 Jun;123(6):1858-67 [12796161.001]
  • [Cites] Thorax. 2003 Jul;58(7):639-41 [12832686.001]
  • [Cites] Thorax. 2003 Oct;58(10):892-900 [14514947.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):5017-26 [14557489.001]
  • [Cites] Cancer Biol Ther. 2004 Jan;3(1):65-70 [14726704.001]
  • [Cites] Thorax. 2004 Jul;59(7):602-7 [15223870.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1403-8 [15178555.001]
  • [Cites] Cancer. 1981 Mar 1;47(5):1042-6 [6261919.001]
  • [Cites] Jpn J Cancer Res. 1987 May;78(5):460-6 [3038811.001]
  • [Cites] Am J Clin Pathol. 1988 Sep;90(3):233-9 [2458030.001]
  • [Cites] Eur J Biochem. 1989 Oct 20;185(1):41-50 [2806262.001]
  • [Cites] Jpn J Cancer Res. 1992 Jan;83(1):93-100 [1544877.001]
  • [Cites] Cell Signal. 1992 Mar;4(2):189-99 [1319722.001]
  • [Cites] Cancer. 1993 May 15;71(10):2971-6 [8387872.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Jul;106(1):90-4 [8391613.001]
  • [Cites] Eur J Biochem. 1994 Oct 1;225(1):21-7 [7925440.001]
  • [Cites] Eur Respir J. 1994 Jul;7(7):1350-64 [7925916.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] EMBO J. 1997 Sep 1;16(17):5433-44 [9312002.001]
  • [Cites] Int J Oncol. 1998 Mar;12(3):553-63 [9472092.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):241-9 [9516978.001]
  • [Cites] Int J Biochem Cell Biol. 1998 Mar;30(3):307-11 [9611773.001]
  • [Cites] Chest. 1999 Apr;115(4):1018-24 [10208203.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3696-703 [10207093.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jul;118(1):145-53 [10384197.001]
  • [Cites] Ann Thorac Surg. 2001 Jun;71(6):1759-64 [11426744.001]
  • (PMID = 15994266.001).
  • [ISSN] 0040-6376
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Microfilament Proteins; 0 / Phosphoproteins; 0 / vasodilator-stimulated phosphoprotein
  • [Other-IDs] NLM/ PMC1747468
  •  go-up   go-down


39. Stanic J, Zaric B, Andjelkovic A, Milovancev A, Andjelkovic D, Eri Z: Clinical presentation, treatment options and outcome in patients with bronchioloalveolar carcinoma. J BUON; 2007 Apr-Jun;12(2):233-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Main radiographic findings were lung consolidation (9; 42.8%), diffuse interstitial infiltrates (6; 28.6%), solitary (4; 19.0%) and multiple pulmonary lesions (2; 9.5%).
  • CONCLUSION: BAC is a special clinical and pathological form of adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / therapy. Lung Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17600878.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


40. Milton DT, Kris MG, Gomez JE, Feinstein MB: Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa). Support Care Cancer; 2005 Jan;13(1):70-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Sputum / secretion

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1999 May;115(5):1465-8 [10334175.001]
  • [Cites] J Formos Med Assoc. 2003 Jun;102(6):407-11 [12923594.001]
  • [Cites] Respir Res. 2001;2(2):85-9 [11686870.001]
  • [Cites] Cancer Sci. 2003 May;94(5):453-8 [12824893.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Ann Thorac Surg. 2002 Nov;74(5):1640-6; discussion 1646-7 [12440623.001]
  • [Cites] World J Surg Oncol. 2003 Jul 1;1(1):8 [12917017.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Eur Respir J. 1994 Dec;7(12):2249-51 [7713212.001]
  • [Cites] Thorax. 1975 Dec;30(6):624-30 [176747.001]
  • (PMID = 15558327.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


41. Saintigny P, Wistuba II, Kim ES: Bronchioloalveolar carcinoma: a translational perspective. Oncology (Williston Park); 2010 Sep;24(10):907-8, 914
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / genetics. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Oncology (Williston Park). 2010 Sep;24(10):888-98, 900 [21138169.001]
  • (PMID = 21138171.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / STK11 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


42. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA Jr, Franklin WA, Crowley J, Gandara DR, Southwest Oncology Group: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol; 2005 Oct 1;23(28):6838-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / genetics. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / genetics. Gene Dosage. Lung Neoplasms / genetics. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adult. Aged. Aged, 80 and over. Female. Genes, erbB-2. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Patient Selection. Predictive Value of Tests. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / physiology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Oct 1;23(28):6813-6 [16145056.001]
  • [CommentIn] J Clin Oncol. 2006 Mar 1;24(7):1219-20; author reply 1220-1 [16505443.001]
  • (PMID = 15998906.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / P30-CA46934; United States / NCI NIH HHS / CA / P50 CA058187
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


43. Bishop JA, Sharma R, Illei PB: Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol; 2010 Jan;41(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
  • Recent advances in the treatment of pulmonary adenocarcinoma have increased the need for accurate typing of non-small cell carcinomas.
  • Immunohistochemistry for thyroid transcription factor-1 is widely used in the diagnosis of pulmonary adenocarcinomas because it marks approximately 75% of lung adenocarcinomas and is negative in most squamous cell carcinomas and adenocarcinomas of other organs.
  • It is detected in the cytoplasm of type 2 pneumocytes and alveolar macrophages and is a putative marker for pulmonary adenocarcinomas.
  • We performed immunohistochemistry for napsin A and thyroid transcription factor-1 using tissue microarrays of 95 adenocarcinomas, 48 squamous cell carcinomas, 6 neuroendocrine tumors of the lung, as well as 5 colonic, 31 pancreatic, and 17 breast adenocarcinomas, 38 malignant mesotheliomas, 118 renal cell carcinomas, and 81 thyroid tumors.
  • Napsin A is a sensitive marker for pulmonary adenocarcinoma and is also expressed in a subset of renal cell carcinomas, particularly of the papillary type, as well as in rare cases of papillary thyroid carcinomas.
  • The combined use of napsin A and thyroid transcription factor-1 results in improved sensitivity and specificity for identifying pulmonary adenocarcinoma in primary lung tumors and in a metastatic setting.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Colonic Neoplasms / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / metabolism. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Pancreatic Neoplasms / metabolism. Thyroid Neoplasms / metabolism. Tissue Array Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2012 Jul;43(7):1153-4; author reply 1154 [22703591.001]
  • (PMID = 19740516.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


44. Minami Y, Matsuno Y, Iijima T, Morishita Y, Onizuka M, Sakakibara Y, Noguchi M: Prognostication of small-sized primary pulmonary adenocarcinomas by histopathological and karyometric analysis. Lung Cancer; 2005 Jun;48(3):339-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To reveal useful prognostic factors in cases of small-sized pulmonary adenocarcinoma, we conducted a histological and karyometric analysis of 116 small-sized pulmonary adenocarcinomas measuring less than 2 cm in maximum diameter and four specimens of atypical adenomatous hyperplasia (AAH).
  • Small adenocarcinoma of the lung.
  • Lung Cancer 1995:75;2844-52].
  • There were 99 tumors of replacement-type adenocarcinoma, comprising 11 type A, localized bronchioloalveolar adenocarcinoma (LBAC); 6 type B, LBAC with alveolar collapse; and 82 type C, LBAC with foci of fibroblastic proliferation.
  • Histological subtypes of type A and B adenocarcinomas, a small F-f ratio, and a small Max ND of type C adenocarcinomas were closely correlated with an excellent prognosis in small-sized adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / genetics. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893002.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


45. Kinoshita Y, Kishi K, Takaya H, Miyamoto A, Sakamoto S, Kurosaki A, Fujii T, Yoshimura K: [A case of desquamative interstitial pneumonia with adenocarcinoma of the lung]. Nihon Kokyuki Gakkai Zasshi; 2007 Nov;45(11):861-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of desquamative interstitial pneumonia with adenocarcinoma of the lung].
  • A 73-year-old woman was admitted to our hospital because of dyspnea on effort and diffuse ground-glass opacities in bilateral lower lung fields on a chest radiograph.
  • Right upper lobectomy and lung biopsy of the right lower lobe were performed using video-assisted thoracoscopic surgery.
  • Histological examination revealed adenocarcinoma in the right S3 and an accumulation of pigmented macrophages in the alveolar spaces of the lower lobe, which was compatible with desquamative interstitial pneumonia (DIP).
  • It is unlikely that the lung cancer and DIP were closely associated etiologically, because the adenocarcinoma was located far from the area of DIP.
  • [MeSH-major] Adenocarcinoma / complications. Lung Diseases, Interstitial / complications. Lung Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18051788.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


46. Borczuk AC, Kim HK, Yegen HA, Friedman RA, Powell CA: Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness. Am J Respir Crit Care Med; 2005 Sep 15;172(6):729-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness.
  • RATIONALE: Lung adenocarcinoma histology and clinical outcome are heterogeneous and associated with tumor invasiveness.
  • OBJECTIVES: We hypothesized that invasiveness is associated with a distinct molecular signature and that genes differentially expressed in tumor or adjacent stroma will identify cell surface signal transduction and matrix remodeling pathways associated with the acquisition of invasiveness in lung adenocarcinoma.
  • MAIN RESULTS: Microarray analysis of microdissected noninvasive bronchioloalveolar carcinoma (BAC) and invasive adenocarcinoma and adenocarcinoma-mixed type with BAC features identified transcriptional profiles of lung adenocarcinoma invasiveness.
  • Among the signature set that was lower in adenocarcinoma-mixed compared with BAC was the type II transforming growth factor beta (TGF-beta) receptor, suggesting downregulation of TGFbetaRII is an early event in lung adenocarcinoma metastasis.
  • Repression of TGFbetaRII in lung cancer cells increased tumor cell invasiveness and activated p38 mitogen-activated protein kinases.
  • Microarray analysis of invasive cells identified potential downstream mediators of TGFbetaRII with differential expression in lung adenocarcinomas.
  • CONCLUSIONS: The repression of type II TGF-beta receptor may act as a significant determinant of lung adenocarcinoma invasiveness, an early step in tumor progression toward metastasis.

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1093-102 [11861388.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2181-90 [12057921.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1551-9 [12070302.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4478-83 [12154058.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3803-12 [12473593.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):1116-24 [14523048.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1949-60 [14578194.001]
  • [Cites] Nat Med. 2004 Feb;10(2):175-81 [14704789.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2359-67 [15073112.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6478-83 [15123840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8431-6 [15152076.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Jul 15;170(2):167-74 [15087295.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4687-92 [15256431.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1632-8 [15378500.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3101-4 [9679977.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4681-7 [10493525.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8208-12 [15548686.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8831-8 [15604241.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2296-302 [15781643.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2096-101 [10601380.001]
  • [Cites] Nature. 2000 Feb 17;403(6771):781-5 [10693808.001]
  • [Cites] J Immunol. 2000 Mar 15;164(6):3222-8 [10706714.001]
  • [Cites] Cell. 2000 Oct 13;103(2):295-309 [11057902.001]
  • [Cites] Exp Lung Res. 2000 Dec;26(8):685-707 [11195465.001]
  • [Cites] Clin Cancer Res. 2001 Feb;7(2):285-9 [11234881.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):169-78 [11252892.001]
  • [Cites] Ann Thorac Surg. 2001 Mar;71(3):971-4 [11269483.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] J Biol Chem. 2001 Dec 14;276(50):46707-13 [11590169.001]
  • [Cites] Eur Respir J. 2001 Dec;18(6):1059-68 [11829087.001]
  • [Cites] Clin Imaging. 2002 Mar-Apr;26(2):95-100 [11852215.001]
  • (PMID = 15976377.001).
  • [ISSN] 1073-449X
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES00354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Transforming Growth Factor beta; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  • [Other-IDs] NLM/ PMC2718552
  •  go-up   go-down


47. Ikeda K, Nomori H, Ohba Y, Shibata H, Mori T, Honda Y, Iyama K, Kobayashi T: Epidermal growth factor receptor mutations in multicentric lung adenocarcinomas and atypical adenomatous hyperplasias. J Thorac Oncol; 2008 May;3(5):467-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor mutations in multicentric lung adenocarcinomas and atypical adenomatous hyperplasias.
  • BACKGROUND: The mechanisms of generation and progression of multicentric lung adenocarcinoma (AD), bronchioloalveolar carcinoma (BAC), and atypical adenomatous hyperplasia (AAH) in the peripheral lung is not well known.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18448997.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


48. Sawada S, Komori E, Nogami N, Segawa Y, Shinkai T, Yamashita M: Evaluation of lesions corresponding to ground-glass opacities that were resected after computed tomography follow-up examination. Lung Cancer; 2009 Aug;65(2):176-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 113 lung cancer patients with pure or mixed GGO findings who underwent a resection after a CT follow-up examination between 1999 and 2005 were retrospectively examined.
  • Histology revealed that adenocarcinoma was found in all 113 patients; squamous cell carcinoma was not found in any of the patients.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Lung Neoplasms / radiography. Lung Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135757.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


49. Garfield DH, Cadranel JL, Wislez M, Franklin WA, Hirsch FR: The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. J Thorac Oncol; 2006 May;1(4):344-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases.
  • Bronchioloalveolar carcinoma (BAC) develops from terminal bronchiolar and acinar epithelia, growing along alveolar septa but without evidence of vascular or pleural involvement.
  • A final diagnosis of BAC can only be achieved from a surgical specimen.
  • The recent interest and potential importance of BAC and the related peripheral adenocarcinoma (ADC), mixed subtype, is attributable to mounting evidence that some, perhaps many, of what are called peripheral ADCs have arisen from and often contain BAC.
  • Clinical characteristics often differ from other types of non-small cell lung cancers.
  • Because of frequent lung-only recurrences, lung transplantation, although performed rarely, may hold promise.
  • [MeSH-major] Adenocarcinoma / therapy. Adenocarcinoma, Bronchiolo-Alveolar / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Lung Transplantation. Male. Neoplasm Invasiveness. Neoplasm Staging. Positron-Emission Tomography. Prognosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Oncol. 2006 Jun;1(5):405
  • (PMID = 17409882.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 058187
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 207
  •  go-up   go-down


50. Fujimoto K: Usefulness of contrast-enhanced magnetic resonance imaging for evaluating solitary pulmonary nodules. Cancer Imaging; 2008;8:36-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Image Enhancement. Lung Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Solitary Pulmonary Nodule / diagnosis
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Carcinoma, Non-Small-Cell Lung / metabolism. Contrast Media. Diagnosis, Differential. Gadolinium. Hamartoma / diagnosis. Humans. Lung Diseases / diagnosis. Pneumonia, Pneumococcal / diagnosis. Positron-Emission Tomography. Prognosis. Sensitivity and Specificity. Tomography, X-Ray Computed. Tuberculoma / diagnosis. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1999 Dec;116(6 Suppl):519S-522S [10619523.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3293-8 [16829653.001]
  • [Cites] Radiographics. 2000 Jan-Feb;20(1):59-66 [10682771.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] J Thorac Imaging. 2002 Apr;17(2):163-6 [11956369.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):89S-96S [12527568.001]
  • [Cites] Radiology. 2003 Jun;227(3):786-93 [12714678.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2535-42 [12815140.001]
  • [Cites] Radiology. 2004 Jun;231(3):872-9 [15163823.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Aug;33(8):913-8 [16572304.001]
  • [Cites] AJR Am J Roentgenol. 2007 Jan;188(1):26-36 [17179342.001]
  • [Cites] Chest. 2007 May;131(5):1516-25 [17494800.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):386-92 [17646465.001]
  • [Cites] Lung Cancer. 2004 Jul;45(1):19-27 [15196730.001]
  • [Cites] Radiology. 2004 Aug;232(2):544-53 [15215548.001]
  • [Cites] Radiology. 2004 Oct;233(1):191-9 [15304661.001]
  • [Cites] Eur J Radiol. 2004 Nov;52(2):144-50 [15489071.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1967 Jul;100(3):603-19 [5230250.001]
  • [Cites] Radiology. 1989 Mar;170(3 Pt 1):637-41 [2916014.001]
  • [Cites] Radiology. 1990 Sep;176(3):749-53 [2167502.001]
  • [Cites] Radiology. 1991 Mar;178(3):705-13 [1847239.001]
  • [Cites] J Thorac Imaging. 1992 Jun;7(3):64-9 [1501268.001]
  • [Cites] Radiology. 1993 Feb;186(2):405-13 [8421743.001]
  • [Cites] J Thorac Imaging. 1994 Winter;9(1):51-5 [8114166.001]
  • [Cites] J Thorac Imaging. 1995 Spring;10(2):91-5 [7769636.001]
  • [Cites] J Magn Reson Imaging. 1997 May-Jun;7(3):564-74 [9170043.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):910-4 [9744306.001]
  • [Cites] Radiology. 1999 Feb;210(2):323-4 [10207409.001]
  • [Cites] Radiology. 2005 Jun;235(3):1084; author reply 1084-5 [15914486.001]
  • [Cites] Radiology. 2005 Nov;237(2):395-400 [16244247.001]
  • [Cites] Cancer Imaging. 2005;5:131-8 [16321775.001]
  • [Cites] Radiology. 2006 Apr;239(1):34-49 [16567482.001]
  • [Cites] Chest. 2006 Apr;129(4):1039-42 [16608955.001]
  • [Cites] Lung Cancer. 2006 Jul;53(1):39-49 [16690161.001]
  • [Cites] Eur J Radiol. 2006 Jul;59(1):60-4 [16530369.001]
  • [Cites] Radiology. 2000 Jan;214(1):73-80 [10644104.001]
  • (PMID = 18331971.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Vascular Endothelial Growth Factor A; AU0V1LM3JT / Gadolinium
  • [Number-of-references] 41
  • [Other-IDs] NLM/ PMC2267694
  •  go-up   go-down


51. Mattarocci S, Abbruzzese C, Mileo AM, Visca P, Antoniani B, Alessandrini G, Facciolo F, Felsani A, Radulescu RT, Paggi MG: Intracellular presence of insulin and its phosphorylated receptor in non-small cell lung cancer. J Cell Physiol; 2009 Dec;221(3):766-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracellular presence of insulin and its phosphorylated receptor in non-small cell lung cancer.
  • In order to delineate the role of insulin specifically in non-small cell lung cancer (NSCLC), we have now searched by immunohistochemistry (IHC) for the presence of insulin in NSCLC samples.
  • Furthermore and interestingly, surrounding atypical adenomatous hyperplastic areas and normal alveolar pneumocytes scored insulin-positive in some of the insulin-negative tumors.
  • Taken together, our data suggest that an intracellular insulin activity is important for the progression of low-grade human lung adenocarcinomas.
  • [MeSH-major] Antigens, CD / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Insulin / metabolism. Intracellular Space / metabolism. Receptor, Insulin / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Aged. Aging / metabolism. Carcinoma, Squamous Cell / metabolism. Cell Membrane / metabolism. Cytoplasm / metabolism. Cytoplasmic Granules / metabolism. Disease-Free Survival. Female. Gene Expression / genetics. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Phosphorylation

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688775.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Insulin; EC 2.7.10.1 / INSR protein, human; EC 2.7.10.1 / Receptor, Insulin
  •  go-up   go-down


52. Bai XY, Shen H: [Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jan;28(1):20-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci].
  • OBJECTIVE: To observe the expression of thyroid transcription factor-1 (TTF-1) mRNA in human normal adult type II alveolar epithelial cells, embryonic alveolar epithelial cells, and primary lung carcinoma and lymph nodes, thereby exploring the role of TTF-1 mRNA expression in the tumorigenesis, development and metastasis of lung carcinoma.
  • RESULTS: TTF-1 mRNA expression was significantly less intense in embryonic lung than in normal adult lung tissues (P= 0.000), and the two tissues both had significantly greater expression than lung adenocarcinoma, squamous cell carcinoma, small cell carcinoma and large cell carcinoma (P=0.000).
  • Lung adenocarcinoma and small cell carcinoma, with similar expression intensity (P= 0.068), showed stronger expression than squamous cell carcinoma and large cell carcinoma (P=0.000), and squamous cell carcinoma showed stronger expression than large cell carcinoma (P=0.018).
  • In lung adenocarcinoma, squamous cell carcinoma and large cell carcinoma, the intensity of TTF-1 mRNA expression was stronger in lymph node metastases than in the primary foci (P=0.003, P=0.000, P=0.019, respectively).
  • The lymph node metastases had more intense expression than the primary foci of small cell lung carcinoma (P=0.078).
  • The intensity of TTF-1 mRNA expression was greater in primary lung carcinomas with lymph node metastases than in those without metastases (P=0.026).
  • CONCLUSION: The amount of TTF-1 mRNA expression lowers in the order of normal adult lung, embryonic lung and lung carcinoma tissues.
  • In lung carcinomas, TTF-1 mRNA expression differs between the histological types, high in lung adenocarcinoma and small cell carcinoma and rather low in squamous cell carcinoma and large cell carcinoma.
  • Strong expression of TTF-1 mRNA often indicates high likeliness of lung carcinoma metastasis, and highlights the high metastatic potentials of lung adenocarcinoma, squamous cell carcinoma and large cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Lung Neoplasms / genetics. Nuclear Proteins / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Female. Humans. In Situ Hybridization. Lymphatic Metastasis. Male. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Thyroid Gland / metabolism. Tissue Array Analysis / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18227018.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


53. Sun Z, Wigle DA, Yang P: Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol; 2008 Feb 20;26(6):877-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival.
  • PURPOSE: Gene expression profiling for outcome prediction of non-small-cell lung cancer (NSCLC) remains clouded by heterogeneous and unvalidated results.
  • MATERIALS AND METHODS: Two NSCLC oligonucleotide microarray data sets of adenocarcinoma and squamous cell carcinoma were used as training sets to select prognostic genes independent of conventional predictors.
  • RESULTS: Adenocarcinomas with the 50-gene signature from adenocarcinoma in both validation data sets had a 2.4-fold (95% CI, 1.3 to 4.4 and 1.0 to 5.8) increased mortality after adjustment for conventional predictors.
  • Adenocarcinoma with the 50-gene signature from squamous cell carcinoma had an elevated risk of 3.5 (95% CI, 1.4 to 9.0) after adjustment for conventional predictors.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / mortality. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / mortality. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / mortality. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Proportional Hazards Models. ROC Curve. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281660.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA115857; United States / NCI NIH HHS / CA / CA80127; United States / NCI NIH HHS / CA / CA84354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Ulmeanu R, Mihăltan F, Crişan E, Alexe M, Grigore P, Andreescu I, Galbenu P, Leonte D: [Practical issues of transbronchial lung biopsy (TLB) in pneumology]. Pneumologia; 2007 Apr-Jun;56(2):59-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Practical issues of transbronchial lung biopsy (TLB) in pneumology].
  • METHOD: We present a survey of 78 TLB which have been performed in Bronchology Service (during 2003-2005) for diffuse interstitial lung diseases--70 cases or located diseases--8 cases; TLB was not performed for solitary peripherally opacities because we have no radiological device with mobile arm (for good position of forceps).
  • RESULTS: In 78% of cases we obtained illustrative lung tissue and in 22% of cases we prelevated just bronchial wall.
  • Histological confirmation was obtained for 53% of cases; 47% of cases have as result lung tissue without significant modifications.
  • Histological diagnosis was obtain in 41% of cases.
  • The diagnosis of lung pathology was: diffuse lung fibrosis, tuberculosis, sarcoidosis stage II-III, malignant lymphoma, carcinomatosis, undifferentiated carcinoma, bronchioloalveolar carcinoma, squamous carcinoma, adenocarcinoma.
  • The international guidelines request that the TLB has to be made before the thoracoscopy or the thoracotomy; because of the small size of prelevated fragments the diagnosis sensibility is variable.
  • Our results for the 78 cases are comparable with the international data from literature both from the point of view of the diagnosis and the complications.
  • [MeSH-major] Biopsy, Needle / methods. Bronchoscopy. Lung Diseases / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Aged. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Granulomatosis with Polyangiitis / pathology. Health Surveys. Humans. Lung Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Practice Guidelines as Topic. Pulmonary Fibrosis / pathology. Sarcoidosis, Pulmonary / pathology. Sensitivity and Specificity. Tuberculosis, Pulmonary / pathology

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019749.001).
  • [ISSN] 2067-2993
  • [Journal-full-title] Pneumologia (Bucharest, Romania)
  • [ISO-abbreviation] Pneumologia
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


55. Yoshida J: Management of the peripheral small ground-glass opacities. Thorac Surg Clin; 2007 May;17(2):191-201, viii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It seems that a lower-impact surgery (eg, wedge resection or segmentectomy) is curative for these lung cancers.
  • Because high-resolution CT seems to predict noninvasive or minimally invasive GGO lung cancers with high reliability, less invasive treatments like radiofrequency ablation have greater appeal.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Lung Neoplasms / radiography. Lung Neoplasms / surgery. Tomography, Spiral Computed / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626397.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


56. Sato S, Koike T, Homma K, Yokoyama A: Ciliated muconodular papillary tumour of the lung: a newly defined low-grade malignant tumour. Interact Cardiovasc Thorac Surg; 2010 Nov;11(5):685-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ciliated muconodular papillary tumour of the lung: a newly defined low-grade malignant tumour.
  • CMPT is a newly defined low-grade malignant tumour with ciliated columnar epithelial cells, occurring in the peripheral lung.
  • The tumours were rich in mucous and had spread along the alveolar walls, as observed in bronchioloalveolar carcinoma.
  • The immunohistochemical staining patterns were almost identical to those of pulmonary adenocarcinoma.
  • [MeSH-major] Epithelial Cells / pathology. Goblet Cells / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology. Solitary Pulmonary Nodule / classification. Solitary Pulmonary Nodule / pathology. Terminology as Topic

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20724424.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


57. Okada M: Invited commentary. Ann Thorac Surg; 2009 Oct;88(4):1111
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Diagnosis, Differential. Disease-Free Survival. Humans. Intraoperative Period. Japan / epidemiology. Survival Rate / trends. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Thorac Surg. 2009 Oct;88(4):1106-11 [19766789.001]
  • (PMID = 19766790.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


58. Smit EF, Dingemans AM, Thunnissen FB, Hochstenbach MM, van Suylen RJ, Postmus PE: Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. J Thorac Oncol; 2010 May;5(5):719-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Mutation / genetics. Proto-Oncogene Proteins / genetics. Pyridines / therapeutic use. ras Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20421765.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / KRAS protein, human; 0 / Phenylurea Compounds; 0 / Proto-Oncogene Proteins; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


59. Goyal A, Chen S: Bronchioloalveolar carcinoma is really carcinoma in situ. Arch Pathol Lab Med; 2008 Oct;132(10):1548
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Carcinoma in Situ / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. World Health Organization

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Arch Pathol Lab Med. 2007 Jul;131(7):1027-32 [17616987.001]
  • (PMID = 18834206.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


60. Ho C, Murray N, Laskin J, Melosky B, Anderson H, Bebb G: Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. Lung Cancer; 2005 Aug;49(2):225-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America.
  • Institutional series suggest specific subgroups of patients with non-small cell lung cancer (NSCLC); female, Asian, non-smokers, respond preferentially to gefitinib.
  • Baseline characteristics at diagnosis; 62% Caucasian, 38% Asian, male 47%, smokers 67%, non-smokers 33%, ECOG 0/1 59%; tumor histology: 57% adenocarcinoma, 13% bronchoalveolar variant, 7% squamous, 23% other.
  • Of the 14 radiological responders, 10 were Asian, 10 ECOG 0/1, 10 female, 8 non-smokers, 8 adenocarcinoma and 4 bronchoalveolar variant.
  • The molecular basis of the improved response rate observed in the subset of female, Asian, non-smokers with adenocarcinoma or bronchoalveolar variant is currently being explored by gene sequencing studies at the British Columbia Cancer Agency Genome Science Centre.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / ethnology. Asian Continental Ancestry Group / ethnology. European Continental Ancestry Group / ethnology. Female. Humans. Male. Middle Aged. North America. Predictive Value of Tests. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925429.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


61. Lindell RM, Hartman TE, Swensen SJ, Jett JR, Midthun DE, Mandrekar JN: 5-year lung cancer screening experience: growth curves of 18 lung cancers compared to histologic type, CT attenuation, stage, survival, and size. Chest; 2009 Dec;136(6):1586-1595
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-year lung cancer screening experience: growth curves of 18 lung cancers compared to histologic type, CT attenuation, stage, survival, and size.
  • BACKGROUND: Although no study has prospectively documented the rate at which lung cancers grow, many have assumed exponential growth.
  • The purpose of this study was to document the growth of lung cancers detected in high-risk participants receiving annual screening chest CT scans.
  • METHODS: Eighteen lung cancers were evaluated by at least four serial CT scans (4 men, 14 women; age range, 53 to 79 years; mean age, 66 years).
  • Cancers associated with higher stages, mortality, or recurrence showed fairly steady growth or accelerated growth compared with earlier growth, although these growth patterns also were seen in lesser-stage lung cancers.
  • Most lung cancers enlarged at fairly steady increments, but several demonstrated fairly flat growth curves, and others demonstrated periods of accelerated growth.
  • CONCLUSIONS: This study is the first to plot individual lung cancer growth curves.
  • Although parameters favored smaller, less aggressive cancers in women, it showed that lung cancers are not limited to exponential growth.
  • Studies and equations assuming exponential growth may potentially misrepresent an indeterminate nodule or the aggressiveness of a lung cancer.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / diagnostic imaging. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / diagnostic imaging. Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Aged. Carcinoma, Non-Small-Cell Lung / diagnostic imaging. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Cell Proliferation. Early Detection of Cancer / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Tumor Burden


62. Wislez M, Beer DG, Wistuba I, Cadranel J, Saijo N, Johnson BE: Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma. J Thorac Oncol; 2006 Nov;1(9 Suppl):S8-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The charge of the Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma Committee was to evaluate the molecular biology, genomic changes, and proteomic findings in patients with bronchioloalveolar carcinoma compared with other types of lung cancer.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / genetics. Genetic Predisposition to Disease. Genomics / methods. Lung Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Biopsy, Needle. DNA Mutational Analysis. DNA, Neoplasm / analysis. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Molecular Biology. Neoplasm Staging. Prognosis. Proteomics / methods. Receptor, Epidermal Growth Factor / genetics. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410000.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 42
  •  go-up   go-down


63. Qu P, Du H, Wang X, Yan C: Matrix metalloproteinase 12 overexpression in lung epithelial cells plays a key role in emphysema to lung bronchioalveolar adenocarcinoma transition. Cancer Res; 2009 Sep 15;69(18):7252-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase 12 overexpression in lung epithelial cells plays a key role in emphysema to lung bronchioalveolar adenocarcinoma transition.
  • Chronic obstructive pulmonary disease (COPD) and lung cancer are two diseases that are related to smoking in humans.
  • Because MMP12 overexpression in epithelial cells has been reported in inflammation-triggered lung remodeling, a murine CCSP-rtTA/(tetO)(7)-MMP12 bitransgenic model was created.
  • In this model, MMP12-Flag fusion protein overexpression and its increased enzymatic activity were observed in the lung in an inducible manner, which led to inflammatory cell infiltration and increased epithelial growth.
  • In sequential events, spontaneous emphysema and bronchioalveolar adenocarcinoma were developed as a result of MMP12 overexpression.
  • During this process, the concentration of interleukin-6 was steadily increased in bronchioalveolar lavage fluid, which activated the oncogenic signal transducer and activator of transcription 3 (Stat3) in alveolar type II epithelial cells.
  • Expression of Stat3 downstream genes that are known to stimulate inflammation and tumor formation was significantly increased in the lung.
  • When tested in humans, MMP12 up-regulation was highly associated with COPD and lung cancer in patients.
  • MMP12 up-regulation plays a critical role in emphysema to lung cancer transition that is facilitated by inflammation.

  • Genetic Alliance. consumer health - Emphysema.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Cell Mol Biol. 2000 Mar;22(3):289-95 [10696065.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):944-56 [19179613.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3838-46 [11090068.001]
  • [Cites] Arch Intern Med. 2003 Jun 23;163(12):1475-80 [12824098.001]
  • [Cites] Immunity. 2004 Feb;20(2):205-18 [14975242.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L801-7 [14644759.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):617-29 [15286728.001]
  • [Cites] J Exp Med. 1975 Aug 1;142(2):361-77 [167096.001]
  • [Cites] J Biol Chem. 1993 Nov 15;268(32):23824-9 [8226919.001]
  • [Cites] Am J Physiol. 1993 Dec;265(6 Pt 1):L521-48 [8279570.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):12189-94 [9115292.001]
  • [Cites] Stem Cells. 1997;15(3):180-9 [9170209.001]
  • [Cites] Nat Med. 1997 Jun;3(6):675-7 [9176496.001]
  • [Cites] Science. 1997 Sep 26;277(5334):2002-4 [9302297.001]
  • [Cites] FASEB J. 1999 May;13(8):781-92 [10224222.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Jun;20(6):1100-2 [10340927.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1086-92 [15709175.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):7250-6 [15905571.001]
  • [Cites] Am J Pathol. 2005 Sep;167(3):813-21 [16127159.001]
  • [Cites] Am J Pathol. 2006 Sep;169(3):916-26 [16936266.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7009-17 [17145822.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33 [17318226.001]
  • [Cites] Lung Cancer. 2007 May;56(2):175-84 [17258348.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1155-66 [17476345.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8494-503 [17875688.001]
  • [Cites] Gene Ther. 2007 Oct;14(20):1461-70 [17700706.001]
  • [Cites] J Immunol. 2009 Feb 1;182(3):1648-59 [19155514.001]
  • [Cites] Lung Cancer. 2009 Mar;63(3):341-7 [18614255.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11858-64 [10766812.001]
  • (PMID = 19706765.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL-061803; United States / NHLBI NIH HHS / HL / R01 HL067862-04; United States / NHLBI NIH HHS / HL / HL067862-05; United States / NHLBI NIH HHS / HL / R01 HL067862-05; United States / NHLBI NIH HHS / HL / R01 HL087001-02; United States / NHLBI NIH HHS / HL / HL087001; United States / NHLBI NIH HHS / HL / R01 HL067862; United States / NHLBI NIH HHS / HL / R01 HL061803-08; United States / NHLBI NIH HHS / HL / R01 HL087001; United States / NHLBI NIH HHS / HL / HL-067862; United States / NHLBI NIH HHS / HL / HL061803-08; United States / NHLBI NIH HHS / HL / HL061803-09; United States / NHLBI NIH HHS / HL / R01 HL061803; United States / NCI NIH HHS / CA / CA138759; United States / NHLBI NIH HHS / HL / HL067862-04; United States / NHLBI NIH HHS / HL / R01 HL061803-09; United States / NHLBI NIH HHS / HL / HL087001-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.65 / Matrix Metalloproteinase 12
  • [Other-IDs] NLM/ NIHMS134473; NLM/ PMC2753283
  •  go-up   go-down


64. Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y, Onimatsu H, Urata Y, Fujiwara T: Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther; 2009 Apr;8(4):980-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer.
  • The present preclinical study investigates whether OBP-301 and a chemotherapeutic agent that is commonly used for lung cancer treatment, gemcitabine, are able to enhance antitumor effects in vitro and in vivo.
  • In vivo antitumor effects of intratumoral injection of OBP-301 in combination with systemic administration of gemcitabine were assessed on nu/nu mice s.c. xenografted with human lung tumors.
  • OBP-301 infection combined with gemcitabine resulted in very potent synergistic cytotoxicity in human lung cancer cells.
  • The three human lung cancer cell lines treated with OBP-301 for 24 hours tended to accumulate in S phase compared with controls.
  • Intratumoral injection of OBP-301 combined with systemic administration of gemcitabine showed therapeutic synergism in human lung tumor xenografts.
  • Our data suggest that the combination of OBP-301 and gemcitabine enhances the antitumor effects against human lung cancer.
  • These results have important implications for the treatment of human lung cancer.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / therapy. Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Large Cell / therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / therapy. Oncolytic Virotherapy. Telomerase / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19372571.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / Ribonucleotide Reductases; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


65. Vahid B, Esmaili A: Erlotinib-associated acute pneumonitis: report of two cases. Can Respir J; 2007 Apr;14(3):167-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first patient was started on erlotinib treatment for metastatic non-small cell lung cancer.
  • The second patient was treated with erlotinib for metastatic adenocarcinoma of unknown origin.
  • Diffuse alveolar hemorrhage was excluded by bronchoscopy in both cases.
  • [MeSH-minor] Acute Disease. Adenocarcinoma / drug therapy. Aged. Carcinoma, Non-Small-Cell Lung / drug therapy. Erlotinib Hydrochloride. Fatal Outcome. Female. Glucocorticoids / administration & dosage. Humans. Lung Neoplasms / drug therapy. Male. Methylprednisolone / administration & dosage. Middle Aged. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Shock, Septic / complications

  • MedlinePlus Health Information. consumer health - Pneumonia.
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):77-85 [14701768.001]
  • [Cites] Lung Cancer. 2004 Jul;45(1):93-104 [15196739.001]
  • [Cites] Br J Cancer. 2004 Aug;91 Suppl 2:S18-23 [15340374.001]
  • [Cites] Br J Cancer. 2004 Aug;91 Suppl 2:S24-30 [15340375.001]
  • [Cites] Br J Cancer. 2004 Aug;91 Suppl 2:S31-7 [15340376.001]
  • [Cites] Can J Urol. 2005 Feb;12 Suppl 1:66-70; discussion 105 [15780170.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Oncologist. 2005 Aug;10(7):461-6 [16079312.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6657-63 [16170173.001]
  • [Cites] Int J Gynecol Cancer. 2005 Sep-Oct;15(5):785-92 [16174225.001]
  • [Cites] J Oncol Pharm Pract. 2005 Sep;11(3):127-30 [16390601.001]
  • (PMID = 17464382.001).
  • [ISSN] 1198-2241
  • [Journal-full-title] Canadian respiratory journal
  • [ISO-abbreviation] Can. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; X4W7ZR7023 / Methylprednisolone
  • [Other-IDs] NLM/ PMC2676839
  •  go-up   go-down


66. Tamura K, Fukuoka M: Gefitinib in non-small cell lung cancer. Expert Opin Pharmacother; 2005 Jun;6(6):985-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib in non-small cell lung cancer.
  • Gefitinib (Iressa), an orally-active tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR), is the first approved molecular-targeted drug for the management of patients with advanced non-small cell lung cancer (NSCLC).
  • Two Phase II trials (IDEAL [Iressa Dose Evaluation in Advanced Lung Cancer]-1 and -2), evaluated the efficacy of gefitinib in advanced NSCLC patients who received < or = 2 (IDEAL1) or > or = 2 (IDEAL2) previous chemotherapy regimens.
  • Furthermore, in a recent randomised, placebo-controlled, Phase III trial (ISEL: IRESSA Survival Evaluation in Lung cancer), gefitinib failed to prolong survival compared with placebo in patients with advanced NSCLC who had failed one or more lines of chemotherapy.
  • In addition, subset analyses of IDEAL and several retrospective studies have indicated that female gender, adenocarcinoma histology (especially bronchial alveolar carcinoma), non-smoker status and Asian ethnicity are factors which predict to response to gefitinib.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use


67. Asamura H: Minimally invasive approach to early, peripheral adenocarcinoma with ground-glass opacity appearance. Ann Thorac Surg; 2008 Feb;85(2):S701-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive approach to early, peripheral adenocarcinoma with ground-glass opacity appearance.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Lung Neoplasms / radiography. Neoplasm Staging / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Pneumonectomy / methods. Risk Assessment. Sensitivity and Specificity. Thoracoscopy / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222200.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 14
  •  go-up   go-down


68. Wislez M, Gounant V, Cadranel J: [Bronchioloalveolar carcinoma]. Rev Mal Respir; 2005 Dec;22(6 Pt 2):8S70-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bronchioloalveolar carcinoma is one of the four histological subtypes of adenocarcinoma and its incidence is increasing.
  • It grows in a lepidic fashion along the alveolar septa without invading alveolar walls.
  • For other types high-resolution lung CT-scan is necessary to evaluate pulmonary involvement because of the high frequency of multifocal disease at initial presentation and because of the presence of ground glass opacities, which can be one of the first manifestations of CBA on CT.
  • Therapeutic management does not differ from non-small cell lung cancer.
  • However, the recent discovery of the particular sensitivity of this form of adenocarcinoma to EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitors offers new possibilities for management.
  • [MeSH-major] Adenocarcinoma. Bronchial Neoplasms. Lung Neoplasms. Pulmonary Alveoli


69. Kim TH, Kim SJ, Ryu YH, Chung SY, Seo JS, Kim YJ, Choi BW, Lee SH, Cho SH: Differential CT features of infectious pneumonia versus bronchioloalveolar carcinoma (BAC) mimicking pneumonia. Eur Radiol; 2006 Aug;16(8):1763-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to evaluate retrospectively the differential CT features of bronchioloalveolar carcinoma (BAC) mimicking pneumonia and infectious pneumonia at the lung periphery.
  • CT images were reviewed in 47 patients with focal areas of parenchymal opacification at the lung periphery.
  • We evaluated the presence of ground-glass attenuation, marginal conspicuity of the lesion, CT angiogram sign, air-bronchogram sign, a bubble-like low-attenuation area within the lesion, presence of pleural thickening and retraction associated with the lesion, presence of pleural effusion and extra-pleural fatty hypertrophy, presence of bronchial wall thickening proximal to the lesion, and air-trapping in the normal lung near the lesion.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnostic imaging. Lung Neoplasms / diagnostic imaging. Pneumonia / diagnostic imaging. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Diagnosis, Differential. Female. Humans. Iohexol / analogs & derivatives. Male. Middle Aged. Predictive Value of Tests. Radiography, Thoracic. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1984 Jan;150(1):15-20 [6316417.001]
  • [Cites] Radiology. 1991 May;179(2):469-76 [2014294.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jun;127(6):1574-8 [15173709.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):525-34 [6329505.001]
  • [Cites] Radiology. 1992 Nov;185(2):401-5 [1329140.001]
  • [Cites] AJR Am J Roentgenol. 1992 Aug;159(2):275-7 [1321558.001]
  • [Cites] J Thorac Imaging. 1995 Spring;10 (2):96-8 [7769637.001]
  • [Cites] Eur Radiol. 1998;8(6):996-1001 [9683709.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17 (4):609-12 [8392527.001]
  • [Cites] Arch Ophthalmol. 1993 Dec;111(12):1627-34 [8155032.001]
  • [Cites] Eur Respir J. 2001 Dec;18(6):1059-68 [11829087.001]
  • [Cites] Eur Radiol. 2005 Oct;15(10 ):2075-8 [15717197.001]
  • [Cites] Radiology. 1996 May;199(2):485-8 [8668800.001]
  • [Cites] Adv Anat Pathol. 2005 Jan;12(1):1-6 [15614158.001]
  • [Cites] Radiology. 1990 Sep;176(3):749-53 [2167502.001]
  • [Cites] Eur Radiol. 1999;9(1):55-9 [9933380.001]
  • [Cites] Adv Intern Med. 1960;10:329-58 [13762021.001]
  • [Cites] Cancer. 1972 Oct;30(4):1107-18 [4342854.001]
  • [Cites] Radiology. 1988 May;167(2):379-82 [2833764.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jan-Feb;21(1):133-5 [9022785.001]
  • [Cites] Chest Surg Clin N Am. 1994 Aug;4(3):405-30 [7953476.001]
  • [Cites] J Thorac Imaging. 1994 Summer;9(3):141-4 [8083927.001]
  • [Cites] J Thorac Imaging. 1995 Spring;10 (2):106-11 [7769623.001]
  • [Cites] Radiol Clin North Am. 1990 May;28(3):583-97 [2158119.001]
  • [Cites] Cancer. 1994 Feb 15;73(4):1163-70 [8313318.001]
  • [Cites] Semin Roentgenol. 1990 Jan;25(1):105-11 [2157287.001]
  • [Cites] Am J Clin Pathol. 1999 Dec;112(6):777-83 [10587700.001]
  • [Cites] Lung Cancer. 2003 Dec;42(3):319-26 [14644520.001]
  • (PMID = 16418864.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide
  •  go-up   go-down


70. Nakanishi K, Matsuo H, Kanai Y, Endou H, Hiroi S, Tominaga S, Mukai M, Ikeda E, Ozeki Y, Aida S, Kawai T: LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Virchows Arch; 2006 Feb;448(2):142-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung.
  • No previous study has investigated neutral large amino acid transporter type 1 (LAT1) in normal lung cells, or in atypical adenomatous hyperplasia(s) (AAH) and nonmucinous bronchioloalveolar carcinoma(s) (NMBAC) of the lung.
  • (1) the levels of LAT1 mRNA/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA in 41 normal lung tissues and 34 NMBAC using semiquantitative reverse transcription-polymerase chain reaction;.
  • (2) LAT1 mRNA and protein expressions in 35 normal lung tissues, 34 AAH (11 lesions were interpreted as low-grade AAH and 23 as high-grade AAH), and 43 NMBAC using in situ hybridization and immunohistochemistry; and (2) the association of the incidences of LAT1 mRNA and protein expressions with cell proliferation in these lesions.
  • The level of LAT1 mRNA/GAPDH mRNA (1) tended to be higher in NMBAC (12.0+/-8.1) than in normal lung tissues (1.0+/-0.2), and (2) covered a much wider range (from 0 to 276) in NMBAC than in normal lung tissues (from 0 to 5.8), with six NMBAC having values higher than 7.0, while 5.8 was the highest value detected in normal lung tissues.
  • In peripheral normal lung tissues, LAT1 mRNA and protein were detected in bronchial surface epithelial cells and alveolar macrophages (but not in nonciliated bronchiolar epithelial cells, or in alveolar type I or type II cells).
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenomatosis, Pulmonary / pathology. Large Neutral Amino Acid-Transporter 1 / genetics. Lung / metabolism. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 May 18;276(20):16877-84 [11278397.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1152-9 [7532544.001]
  • [Cites] Mod Pathol. 2001 Feb;14(2):72-84 [11235908.001]
  • [Cites] Curr Drug Metab. 2001 Dec;2(4):339-54 [11766986.001]
  • [Cites] Nucleic Acids Res. 1989 Mar 11;17(5):1915-31 [2928113.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):712-9 [14608897.001]
  • [Cites] Nature. 1998 Sep 17;395(6699):288-91 [9751058.001]
  • [Cites] Hum Pathol. 2002 Jul;33(7):697-702 [12196920.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1105-11 [12631614.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1761-72 [12414523.001]
  • [Cites] Hum Pathol. 1998 Mar;29(3):235-9 [9496825.001]
  • [Cites] J Biol Chem. 1999 Jul 9;274(28):19745-51 [10391916.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Dec;281(6):F995-1018 [11704550.001]
  • [Cites] Biochim Biophys Acta. 2003 Apr 1;1611(1-2):81-90 [12659948.001]
  • [Cites] Neuroreport. 2000 Nov 9;11(16):3507-11 [11095508.001]
  • [Cites] Arch Pathol Lab Med. 1990 Apr;114(4):363-8 [2322096.001]
  • [Cites] J Toxicol Sci. 2003 Feb;28(1):1-17 [12696180.001]
  • [Cites] J Surg Oncol. 2001 Dec;78(4):265-71; discussion 271-2 [11745822.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Biol Chem. 1998 Sep 11;273(37):23629-32 [9726963.001]
  • [Cites] Physiol Rev. 1990 Jan;70(1):43-77 [2404290.001]
  • [Cites] Biochim Biophys Acta. 2002 Sep 20;1565(1):112-21 [12225859.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):610-22 [10230351.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):5012-22 [8895758.001]
  • (PMID = 16175382.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Large Neutral Amino Acid-Transporter 1; 0 / RNA, Messenger
  •  go-up   go-down


71. Priest JR, Williams GM, Hill DA, Dehner LP, Jaffé A: Pulmonary cysts in early childhood and the risk of malignancy. Pediatr Pulmonol; 2009 Jan;44(1):14-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery for congenital and early childhood lung cysts is often dictated by symptoms such as respiratory distress, infection or pneumothorax.
  • Pleuropulmonary blastoma (PPB) is the most frequent malignancy associated with childhood lung cysts.
  • The earliest manifestation of PPB is a malignant lung cyst in young children, clinically and radiographically indistinguishable from benign congenital lung cysts.
  • Numerous reports of "malignancy in a congenital lung cyst" are now understood as the characteristic progression of cystic PPB.
  • Detailed family history may reveal the hallmarks of PPB in the patient or young relatives: a unique constellation of diseases including lung cysts, cystic nephroma, childhood cancers, stromal sex-chord ovarian tumors, seminomas or dysgerminomas, intestinal polyps, thyroid hyperplasias, and hamartomas.
  • Pneumothorax and multifocal/bilateral lung cysts also characterize PPB.
  • These diagnoses predict that a lung cyst is more likely PPB than a benign congenital cyst.
  • Patients fitting this pattern deserve histologic diagnosis.
  • [MeSH-major] Cysts / pathology. Lung Diseases / pathology. Lung Neoplasms / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Child. Diagnosis, Differential. Genetic Predisposition to Disease. Humans. Pulmonary Blastoma / pathology. Risk Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Pulmonol. 2010 Jan;45(1):103; author reply 104 [19960525.001]
  • (PMID = 19061226.001).
  • [ISSN] 1099-0496
  • [Journal-full-title] Pediatric pulmonology
  • [ISO-abbreviation] Pediatr. Pulmonol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


72. Roberts HC, Patsios D, Paul NS, McGregor M, Weisbrod G, Chung T, Herman S, Boerner S, Waddell T, Keshavjee S, Darling G, Pereira A, Kale A, Bayanati H, Sitartchouk I, Tsao M, Shepherd FA: Lung cancer screening with low-dose computed tomography: Canadian experience. Can Assoc Radiol J; 2007 Oct;58(4):225-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer screening with low-dose computed tomography: Canadian experience.
  • INTRODUCTION: In 2003, the Department of Medical Imaging at the University Health Network in Toronto, Ontario, became the first Canadian site of the Intemational Early Lung Cancer Action Program (I-ELCAP).
  • Of the malignancies, 20 are lung carcinomas: 19 non-small-cell lung carcinomas (NSCLCs) (14 adenocarcinoma or bronchioalveolar carcinoma [BAC], 4 squamous carcinoma, and 1 large-cell carcinoma) and 1 small-cell carcinoma; 15 (78%) of the NSCLCs are Stage I.
  • CONCLUSION: Our results confirm that LDCT identifies small, early-stage, resectable lung cancer in a high-risk population.
  • [MeSH-major] Lung Neoplasms / radiography. Mass Screening / methods. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adenocarcinoma / radiography. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Aged. Biopsy / methods. Bronchoscopy. Canada. Carcinoma / radiography. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Squamous Cell / radiography. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Radiation Dosage. Radiography, Interventional. Retrospective Studies. Smoking. Ultrasonography, Interventional

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18186434.001).
  • [ISSN] 0846-5371
  • [Journal-full-title] Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes
  • [ISO-abbreviation] Can Assoc Radiol J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


73. Singh PK, Jain R, Mishra S, Kumar S, Bhatnagar S, Deo S: Management of pericatheter cerebrospinal fluid leak after intrathecal implantation of a drug delivery system. Am J Hosp Palliat Care; 2008 Jun-Jul;25(3):237-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / complications. Adult. Analgesics, Opioid / administration & dosage. Catheters, Indwelling / adverse effects. Dura Mater / injuries. Female. Humans. Lung Neoplasms / complications. Morphine / administration & dosage. Pain / drug therapy. Pain / etiology. Palliative Care / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Cerebrospinal Fluid Leak.
  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18573999.001).
  • [ISSN] 1938-2715
  • [Journal-full-title] The American journal of hospice & palliative care
  • [ISO-abbreviation] Am J Hosp Palliat Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine
  •  go-up   go-down


74. Yamaguchi Y, Ishii G, Kojima M, Yoh K, Otsuka H, Otaki Y, Aokage K, Yanagi S, Nagai K, Nishiwaki Y, Ochiai A: Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness. J Thorac Oncol; 2010 Sep;5(9):1361-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness.
  • The purpose of this study was to evaluate the clinicopathologic significance of tumor budding in adenocarcinomas of the lung.
  • METHODS: We investigated the relationship between tumor budding and clinicopathologic parameters of adenocarcinomas of the lung and the prognostic significance of tumor budding by reviewing the cases of 201 consecutive patients who had undergone complete resection of adenocarcinoma of the lung measuring 30 mm or less in diameter.
  • RESULTS: Tumor budding was observed in 78 (43.1%) of the 181 cases with invasive adenocarcinoma.
  • Multivariate analysis revealed that tumor budding was significant independent prognostic factor of the small-sized adenocarcinoma of the lung.
  • CONCLUSIONS: Our data showed that tumor budding in adenocarcinoma of the lung is a distinct morphologic feature that has biologic and prognostic significance.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / pathology. Lung Neoplasms / pathology. Pleural Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631633.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / beta Catenin; 0 / kalinin
  •  go-up   go-down


75. Venkata C, Mireles JA, Venkateshiah SB: Refractory hypoxemic respiratory failure due to adenocarcinoma of the lung with predominant bronchioloalveolar carcinoma component. Respir Care; 2009 Nov;54(11):1496-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory hypoxemic respiratory failure due to adenocarcinoma of the lung with predominant bronchioloalveolar carcinoma component.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / complications. Anoxia / etiology. Lung Neoplasms / complications. Respiratory Insufficiency / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863835.001).
  • [ISSN] 0020-1324
  • [Journal-full-title] Respiratory care
  • [ISO-abbreviation] Respir Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Oda S, Awai K, Liu D, Nakaura T, Yanaga Y, Nomori H, Yamashita Y: Ground-glass opacities on thin-section helical CT: differentiation between bronchioloalveolar carcinoma and atypical adenomatous hyperplasia. AJR Am J Roentgenol; 2008 May;190(5):1363-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / radiography. Lung Neoplasms / radiography. Solitary Pulmonary Nodule / radiography. Tomography, Spiral Computed
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Hyperplasia / radiography. Male. Middle Aged. Observer Variation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18430856.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Tsurutani J, Ballas MS, Dennis PA: Overestimating the influence of the 1999 WHO classification of lung tumors on survival in bronchioloalveloar carcinoma. J Clin Oncol; 2006 Apr 20;24(12):1963; author reply 1963-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overestimating the influence of the 1999 WHO classification of lung tumors on survival in bronchioloalveloar carcinoma.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / classification. Adenocarcinoma, Bronchiolo-Alveolar / mortality. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / classification. Lung Neoplasms / mortality. World Health Organization

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2005 Nov 20;23(33):8396-405 [16293870.001]
  • (PMID = 16622278.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


78. Gao YS, Zhang DC, He J, Sun KL, Zhang DW, Zhang RG: [Diagnosis and surgical treatment for stage I non-small-cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2005 Jan;27(1):52-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical treatment for stage I non-small-cell lung cancer].
  • OBJECTIVE: To evaluate the results of surgery and the diagnosis of stage I non-small-cell lung cancer (NSCLC).
  • The 5-year survival rates for patients with squamous-cell carcinoma, adenocarcinoma, adenosquamous and alveolar-cell carcinoma were 73.3%, 55.3%, 52.2%, 71.7%, respectively.
  • The 1-, 3-, 5-year survival rates for T1N0 were 95.0%, 83.2%, 74.3% whereas those of T2N0 lung lesions were 90.8%, 75.9%, 59.9% (P < 0.05).
  • CONCLUSION: The 5-year survival rate of pathologic stage I non-small-cell lung cancer is 66.1%.
  • The outcome of patients with squamous-cell carcinoma (73.3%) is similar to that of alveolar-cell carcinoma (71.7%) which, however, is better than that of adenocarcinoma (55.3%) or adenosquamouscarcinoma (52.5%).
  • Regular lobectomy plus radical mediastinal lymph node dissection is the appropriate management for stage I non-small-cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Lymph Node Excision. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771801.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


79. Kuroda N, Hamaguchi N, Takeuchi E, Ohara M, Hirouchi T, Mizuno K: Lung adenocarcinoma with a micropapillary pattern: a clinicopathological study of 25 cases. APMIS; 2006 May;114(5):381-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma with a micropapillary pattern: a clinicopathological study of 25 cases.
  • Lung adenocarcinoma with a micropapillary pattern has recently been described, but its biological behavior is as yet uncertain.
  • In this article we present a clinicopathological study of lung adenocarcinoma with micropapillary morphology.
  • We selected 25 patients with lung adenocarcinoma with micropapillary morphology from the 2001-2004 pathology files (age range 54 to 81 years; mean 64.5 years).
  • Micropapillary carcinoma is predominantly located at the periphery of the tumor nodule or mass and occurs irrespective of the subtype of the adenocarcinoma.
  • Four cases showed intensive invasive growth such as micropapillary adenocarcinoma of the breast and 21 showed alveolar type morphology with piling-up of the neoplastic cells with or without stromal invasion.
  • Regarding clinical outcome, 14 patients were alive without disease, 5 were alive with disease, and 5 died of the lung adenocarcinoma.
  • However, the carcinoma seen in the five patients who died showed breast type histology with intensive invasive growth in three cases and alveolar type histology with intensive stromal invasion in two.
  • Lung micropapillary carcinoma of breast type may behave more aggressively than the alveolar type.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Papillary / pathology. Aged. Aged, 80 and over. Calcinosis / pathology. Carcinoma, Acinar Cell / pathology. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pleura / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16725015.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


80. Okita R, Yamashita M, Nakata M, Teramoto N, Bessho A, Mogami H: Multiple ground-glass opacity in metastasis of malignant melanoma diagnosed by lung biopsy. Ann Thorac Surg; 2005 Jan;79(1):e1-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple ground-glass opacity in metastasis of malignant melanoma diagnosed by lung biopsy.
  • Focal ground-glass opacity (GGO) on computed tomography has been reported in several disorders including inflammatory disease and primary neoplastic lesion of the lung.
  • Lung biopsy specimen demonstrated melanoma cells proliferating in a lepidic fashion along the thickened alveolar wall simulating bronchioloalveolar carcinoma.
  • Metastatic lung tumor showing GGO is uncommon.
  • [MeSH-major] Lung Neoplasms / radiography. Lung Neoplasms / secondary. Melanoma / radiography. Melanoma / secondary. Nasal Cavity / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / radiography. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Dacarbazine / therapeutic use. Diagnosis, Differential. Female. Humans. Melanocytes / pathology. Middle Aged. Picibanil / administration & dosage. Tegafur / administration & dosage. Tomography, X-Ray Computed. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620900.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 1548R74NSZ / Tegafur; 39325-01-4 / Picibanil; 56HH86ZVCT / Uracil; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


81. Sagawa M, Higashi K, Usuda K, Aikawa H, Machida Y, Tanaka M, Ueno M, Sakuma T: Curative wedge resection for non-invasive bronchioloalveolar carcinoma. Tohoku J Exp Med; 2009 Feb;217(2):133-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pure bronchioloalveolar carcinomas have no stromal, vascular or pleural invasion, and they are candidates for curative wedge resection, although standard operative procedure for lung cancer is a pulmonary lobectomy.
  • Most lung cancers with ground glass opacity (GGO), namely faint homogeneous shadows with sharp margin, are pure bronchioloalveolar carcinomas.
  • 1) clinically no nodal or distant metastasis, 2) the location of the tumor was peripheral enough to undergo wedge resection, 3) the diameter of the shadow was 8-20 mm, 4) GGO% (diameter of GGO area/diameter of whole tumor) was 80% or over, 5) FDG uptake of the tumor was less than that of the mediastinum, 6) the intraoperative pathological diagnosis was non-invasive bronchioloalveolar carcinoma, and 7) informed consent was obtained.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / surgery
  • [MeSH-minor] Aged. Female. Fluorodeoxyglucose F18. Humans. Lung Neoplasms / physiopathology. Lung Neoplasms / radiography. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / surgery. Male. Middle Aged. Positron-Emission Tomography. Respiratory Function Tests. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212106.001).
  • [ISSN] 1349-3329
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


82. Keating DT, Sadlier DM, Patricelli A, Smith SM, Walls D, Egan JJ, Doran PP: Microarray identifies ADAM family members as key responders to TGF-beta1 in alveolar epithelial cells. Respir Res; 2006;7:114
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray identifies ADAM family members as key responders to TGF-beta1 in alveolar epithelial cells.
  • Transforming Growth Factor beta 1(TGF-beta1) is a key effector cytokine in the development of lung fibrosis.
  • We used microarray and computational biology strategies to identify genes whose expression is significantly altered in alveolar epithelial cells (A549) in response to TGF-beta1, IL-4 and IL-13 and Epstein Barr virus.
  • [MeSH-minor] Adenocarcinoma. Cell Line, Tumor. Coculture Techniques. Humans. RNA / genetics. RNA / isolation & purification

  • MedlinePlus Health Information. consumer health - Pulmonary Fibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 1999 Dec;58(12):770-2 [10577965.001]
  • [Cites] Clin Chest Med. 2004 Dec;25(4):749-58, vii [15564020.001]
  • [Cites] J Mol Cell Cardiol. 2000 Feb;32(2):233-46 [10722800.001]
  • [Cites] Thorax. 2000 Nov;55(11):958-61 [11050267.001]
  • [Cites] Ann Intern Med. 2001 Jan 16;134(2):136-51 [11177318.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Feb;280(2):L316-25 [11159011.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 May;24(5):591-8 [11350829.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):809-21 [11560996.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Sep;25(3):385-91 [11588018.001]
  • [Cites] J Clin Invest. 2002 Jan;109(1):41-50 [11781349.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304 [11790668.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3784-92 [11724793.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1607-15 [12070308.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jul 15;166(2):236-46 [12119236.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Aug 15;166(4):510-3 [12186829.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Biochim Biophys Acta. 2003 Apr 15;1626(1-3):83-91 [12697333.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3775-81 [12824416.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Sep;285(3):L527-39 [12598227.001]
  • [Cites] J Immunol. 2003 Sep 1;171(5):2684-93 [12928422.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):598-606 [14519395.001]
  • [Cites] Int Arch Allergy Immunol. 2003 Oct;132(2):168-76 [14600429.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):96-104 [14673146.001]
  • [Cites] Clin Exp Allergy. 2004 May;34(5):757-60 [15144468.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29670-80 [15033991.001]
  • [Cites] Lancet. 1984 Oct 6;2(8406):768-71 [6148520.001]
  • [Cites] Lancet. 1985 Apr 20;1(8434):889-92 [2858744.001]
  • [Cites] J Virol. 1986 Apr;58(1):233-7 [3005654.001]
  • [Cites] Am Rev Respir Dis. 1986 Sep;134(3):566-71 [2428273.001]
  • [Cites] Virus Genes. 1991 Apr;5(2):147-56 [1647567.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):770-4 [8421714.001]
  • [Cites] Thorax. 1993 Oct;48(10):959-66 [7504843.001]
  • [Cites] Histopathology. 1994 Feb;24(2):145-50 [8181807.001]
  • [Cites] J Leukoc Biol. 1996 Jun;59(6):769-74 [8691059.001]
  • [Cites] J Clin Invest. 1997 Aug 15;100(4):768-76 [9259574.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Jan;18(1):60-5 [9448046.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1329-33 [9809560.001]
  • [Cites] Cell. 1999 Feb 5;96(3):319-28 [10025398.001]
  • [Cites] Am J Physiol. 1999 May;276(5 Pt 1):L697-704 [10330024.001]
  • [Cites] J Clin Invest. 1999 Jul;104(1):13-9 [10393694.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23349-57 [10438512.001]
  • [Cites] Respirology. 1999 Dec;4(4):383-91 [10612573.001]
  • (PMID = 16948840.001).
  • [ISSN] 1465-993X
  • [Journal-full-title] Respiratory research
  • [ISO-abbreviation] Respir. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta; 63231-63-0 / RNA; EC 3.4.24.- / ADAM Proteins
  • [Other-IDs] NLM/ PMC1569837
  •  go-up   go-down


83. Caino MC, Oliva JL, Jiang H, Penning TM, Kazanietz MG: Benzo[a]pyrene-7,8-dihydrodiol promotes checkpoint activation and G2/M arrest in human bronchoalveolar carcinoma H358 cells. Mol Pharmacol; 2007 Mar;71(3):744-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our data suggest that a p53-independent pathway operates in lung epithelial cells in response to BPD that involves P450 induction and subsequent activation of the ATR/ATM/Chk1 damage check-point pathway and cell cycle arrest in G2/M.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Cell Division / drug effects. Dihydroxydihydrobenzopyrenes / pharmacology. G2 Phase / drug effects. Lung Neoplasms / pathology. Protein Kinases / physiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114299.001).
  • [ISSN] 0026-895X
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / P01-DA92573; United States / NIEHS NIH HHS / ES / P30-ES013508
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dihydroxydihydrobenzopyrenes; 13345-25-0 / benzo(a)pyrene 7,8-dihydrodiol; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / Checkpoint kinase 1
  •  go-up   go-down


84. Mun M, Kohno T: Single-stage surgical treatment of synchronous bilateral multiple lung cancers. Ann Thorac Surg; 2007 Mar;83(3):1146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-stage surgical treatment of synchronous bilateral multiple lung cancers.
  • BACKGROUND: The rate of detection of synchronous bilateral multiple lung cancers (SBMLC) has increased.
  • METHODS: In a retrospective examination of 674 patients who underwent surgical treatment of primary lung cancers at our department between 1999 and 2004, single-stage surgical treatment was used in 19 patients.
  • [MeSH-major] Adenocarcinoma / surgery. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Neoplasms, Second Primary / surgery. Pneumonectomy / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lung Diseases / etiology. Male. Middle Aged. Neoplasm Recurrence, Local. Pneumonia / etiology. Respiratory Tract Fistula / etiology. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17307478.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


85. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I: Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol; 2006 Mar;1(3):231-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.
  • BACKGROUND: The authors sought to define clinicopathologic features associated with mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC).
  • EGFR mutations were associated with adenocarcinoma (p = 0.002), female gender (p = 0.02), never-smoking (p < 0.0001), Asian ethnicity (p = 0.005), air bronchograms (p = 0.004), and multiple wedge resections (p = 0.03).
  • Asian women with the EGFR mutation developed adenocarcinoma at an earlier age than other lung cancer patients.
  • [MeSH-major] Asian Continental Ancestry Group. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adult. African Americans. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / genetics. European Continental Ancestry Group. Exons. Female. Hispanic Americans. Humans. Male. Middle Aged. Survival Analysis. United States. ras Proteins


86. Lorusso V, Gebbia V, Spada M, Guida M, Cassano G, Brunetti C, Germano D, Nettis G, Izzi G, Galetta D, Giampaglia M, Silvestris N, Colucci G: Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. Oncol Rep; 2005 Dec;14(6):1547-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
  • A number of second line treatments have been proposed in patients with advanced pretreated non-small cell lung cancer (NSCLC).
  • The median age was 63 years (range 43-76); cell types were: squamous carcinoma (n=17), adenocarcinoma (n=16), large cell carcinoma (n=3), broncho-alveolar carcinoma (n=2) and undifferentiated carcinoma (n=4).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy


87. Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, Teruya-Feldstein J, Gerald WL, Ladanyi M, Pandolfi PP: Identification of DOK genes as lung tumor suppressors. Nat Genet; 2010 Mar;42(3):216-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of DOK genes as lung tumor suppressors.
  • Genome-wide analyses of human lung adenocarcinoma have identified regions of consistent copy-number gain or loss, but in many cases the oncogenes and tumor suppressors presumed to reside in these loci remain to be determined.
  • Here we identify the downstream of tyrosine kinase (Dok) family members Dok1, Dok2 and Dok3 as lung tumor suppressors.
  • Single, double or triple compound loss of these genes in mice results in lung cancer, with penetrance and latency dependent on the number of lost Dok alleles.
  • Cancer development is preceded by an aberrant expansion and signaling profile of alveolar type II cells and bronchioalveolar stem cells.
  • In human lung adenocarcinoma, we identify DOK2 as a target of copy-number loss and mRNA downregulation and find that DOK2 suppresses lung cancer cell proliferation in vitro and in vivo.
  • Given the genomic localization of DOK2, we propose it as an 8p21.3 haploinsufficient human lung tumor suppressor.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / physiology. Adenocarcinoma / genetics. DNA-Binding Proteins / physiology. Lung Neoplasms / genetics. Phosphoproteins / physiology. RNA-Binding Proteins / physiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8314-25 [10567556.001]
  • [Cites] Oncogene. 2009 Aug 6;28(31):2773-83 [19525976.001]
  • [Cites] EMBO J. 2000 Oct 2;19(19):5114-22 [11013214.001]
  • [Cites] J Cell Biol. 2001 Jul 23;154(2):345-54 [11470823.001]
  • [Cites] J Exp Med. 2001 Aug 6;194(3):275-84 [11489947.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):97-102 [12051643.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] J Biol Chem. 2004 Oct 1;279(40):42072-81 [15286081.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5368-72 [1356616.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):1172-4 [8439963.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Jun;7(2):85-8 [7687457.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5390-5 [7585607.001]
  • [Cites] J Natl Cancer Inst. 1996 Nov 20;88(22):1676-82 [8931613.001]
  • [Cites] Cell. 1997 Jan 24;88(2):197-204 [9008160.001]
  • [Cites] Cell. 1997 Jan 24;88(2):205-11 [9008161.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):4827-30 [9478921.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1973-9 [10213509.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1057-60 [10508618.001]
  • [Cites] J Exp Med. 2004 Dec 20;200(12):1681-7 [15611294.001]
  • [Cites] J Exp Med. 2004 Dec 20;200(12):1689-95 [15611295.001]
  • [Cites] J Exp Med. 2005 Feb 7;201(3):333-9 [15699069.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):565-72 [15701842.001]
  • [Cites] Cell. 2005 Apr 22;121(2):179-93 [15851026.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30 [15983384.001]
  • [Cites] Am J Pathol. 2005 Dec;167(6):1763-75 [16314486.001]
  • [Cites] Int J Hematol. 2005 Dec;82(5):389-96 [16533740.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(7):2479-89 [16537894.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):3958-65 [16547230.001]
  • [Cites] Science. 2006 Jun 23;312(5781):1802-5 [16794080.001]
  • [Cites] Int Immunol. 2007 Apr;19(4):487-95 [17329234.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3162-70 [17409423.001]
  • [Cites] Nat Genet. 2007 Jun;39(6):750-8 [17468755.001]
  • [Cites] Blood. 2007 Jul 1;110(1):259-66 [17363732.001]
  • [Cites] BMC Genomics. 2007;8:140 [17540040.001]
  • [Cites] J Biochem. 2007 Aug;142(2):257-63 [17827176.001]
  • [Cites] J Clin Invest. 2007 Oct;117(10):2929-40 [17909629.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Genes Dev. 2000 Jan 1;14(1):11-6 [10640270.001]
  • (PMID = 20139980.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA129243-049001; United States / NCI NIH HHS / CA / R01 CA132591; United States / NCI NIH HHS / CA / P01 CA064593; United States / NCI NIH HHS / CA / CA-64593; United States / NCI NIH HHS / CA / R01 CA142787; United States / NCI NIH HHS / CA / CA-129243; United States / NCI NIH HHS / CA / P01 CA129243; United States / NCI NIH HHS / CA / P01 CA064593-08A20002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / Dok1 protein, mouse; 0 / Dok2 protein, mouse; 0 / Dok3 protein, mouse; 0 / Phosphoproteins; 0 / RNA-Binding Proteins
  • [Other-IDs] NLM/ NIHMS235505; NLM/ PMC2956443
  •  go-up   go-down


88. Rami-Porta R, Tsuboi M: Sublobar resection for lung cancer. Eur Respir J; 2009 Feb;33(2):426-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sublobar resection for lung cancer.
  • Sublobar resection for small lung cancers has been debated frequently and is still a controversial issue.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / surgery. Bronchial Neoplasms / surgery. Carcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19181916.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Switzerland
  •  go-up   go-down


89. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M: Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol; 2005 Jul-Aug;26(4):195-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma.
  • Aggrus (T1alpha/podoplanin, known as a specific marker for type I alveolar cells or lymphatic endothelial cells) is a transmembrane sialoglycoprotein that aggregates platelets.
  • The present study investigates Aggrus expression in human primary lung cancer tissues of different types.
  • Immunohistochemical analysis also showed that the incidence of positive staining in sections of squamous cell carcinoma (7/8; 87.5%) was higher than that in adenocarcinoma (2/13; 15.4%).
  • These findings indicated that overexpression of Aggrus occurred in squamous cell carcinoma of the lung.
  • Therefore, Aggrus could be a useful diagnostic marker for squamous cell carcinoma of the lung.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Membrane Proteins / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16006773.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / T1A-2 protein, human
  •  go-up   go-down


90. Schmidt L, Myers J: Bronchioloalveolar carcinoma and the significance of invasion: predicting biologic behavior. Arch Pathol Lab Med; 2010 Oct;134(10):1450-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A resected adenocarcinoma illustrates challenges in diagnosing bronchioloalveolar carcinoma (BAC).
  • The term microinvasive adenocarcinoma or minimally invasive adenocarcinoma has been proposed for otherwise typical BACs and small invasive foci measuring 0.5 cm or less.
  • Larger areas of invasion are associated with a more aggressive course and more reliably distinguish BAC from other variants of adenocarcinoma.
  • Separating BAC from other forms of adenocarcinoma is important owing to differences in prognosis and emerging therapeutic strategies.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20923299.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. West HL, Garfield DH: Bronchioloalveolar carcinoma: not as easy as "BAC". J Thorac Oncol; 2009 Sep;4(9):1047-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Thorac Oncol. 2009 Sep;4(9):1126-35 [19574932.001]
  • (PMID = 19704334.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


92. Kim KS, Jeong JY, Kim YC, Na KJ, Kim YH, Ahn SJ, Baek SM, Park CS, Park CM, Kim YI, Lim SC, Park KO: Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res; 2005 Mar 15;11(6):2244-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of the response to gefitinib in refractory non-small cell lung cancer.
  • Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has a response rate of 10% to 20% in refractory non-small cell lung carcinoma.
  • Although female gender, adenocarcinoma, and never having smoked are possible markers of a favorable response, mutations of the EGFR gene have also been reported to be highly significant predictors of response.
  • Seventy patients with relapsed non-small cell lung carcinoma were enrolled in the Expanded Access Program.
  • The response rate was significantly higher for adenocarcinoma (41.0%) versus non-adenocarcinoma (9.8%, P = 0.001), in those who never smoked (58.8%) versus smokers (15.9%, P < 0.001), and in females (42.1%) versus males (19.7%, P = 0.049).
  • In a multivariate logistic analysis, the independent predictors of response were smoking history and adenocarcinoma.
  • Given that 9.5% of smokers and 6.7% of those with non-adenocarcinoma showed a mutation of the EGFR gene, the genetic profile may replace those variables as an independent predictor of a response.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adult. Aged. Aged, 80 and over. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. Disease Progression. Feasibility Studies. Female. Humans. Male. Middle Aged. Mutation. Predictive Value of Tests. Prognosis. Remission Induction. Salvage Therapy. Survival Rate. Treatment Outcome


93. Huang P, Duda DG, Jain RK, Fukumura D: Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice. Comp Med; 2008 Jun;58(3):253-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All tumors in male mice were lung alveolar-bronchiolar (AB) neoplasms, except for 1 testis interstitial cell tumor.
  • In female mice, histopathologic examination revealed 48 lung AB tumors, 27 mammary gland tumors, 13 ovarian tumors, and 14 other tumors.
  • One mammary adenocarcinoma (MCaP0008) and 1 lung AB carcinoma (LAP0297) were successfully transplanted subcutaneously and passaged serially in vivo.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genesis. 2000 Oct;28(2):75-81 [11064424.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2774-6 [16339405.001]
  • [Cites] Toxicol Ind Health. 2001 Feb;17(1):7-16 [12004924.001]
  • [Cites] Mol Imaging. 2002 Jan-Mar;1(1):9-15 [12920856.001]
  • [Cites] Comp Med. 2003 Aug;53(4):424-32 [14524419.001]
  • [Cites] Comp Med. 2003 Aug;53(4):433-8 [14524420.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5920-4 [15342367.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2065-9 [1848692.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6553-60 [1384965.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):308-15 [7616277.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):73-81 [8961371.001]
  • [Cites] Toxicol Pathol. 1996 Nov-Dec;24(6):710-6 [8994298.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3058-63 [9096345.001]
  • [Cites] Cell. 1998 Sep 18;94(6):715-25 [9753319.001]
  • [Cites] Comp Med. 2005 Jun;55(3):231-5 [16089170.001]
  • [Cites] Comp Med. 2005 Jun;55(3):236-43 [16089171.001]
  • [Cites] Nat Med. 2001 Jul;7(7):864-8 [11433354.001]
  • (PMID = 18589867.001).
  • [ISSN] 1532-0820
  • [Journal-full-title] Comparative medicine
  • [ISO-abbreviation] Comp. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA115767-04; United States / NCI NIH HHS / CA / R01 CA085140; United States / NCI NIH HHS / CA / R01-CA115767; United States / NCI NIH HHS / CA / P01 CA080124; United States / NCI NIH HHS / CA / R01-CA85140; United States / NCI NIH HHS / CA / R01 CA115767; United States / NCI NIH HHS / CA / R01 CA096915; United States / NCI NIH HHS / CA / R01 CA085140-08; United States / NCI NIH HHS / CA / P01 CA080124-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS108990; NLM/ PMC2693079
  •  go-up   go-down


94. Li Y, Zhang XR, Sun Y: [Clinical characteristics and chemotherapy of advanced-stage bronchioloalveolar carcinoma of the lung: report of 53 patients]. Zhonghua Zhong Liu Za Zhi; 2007 Apr;29(4):298-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and chemotherapy of advanced-stage bronchioloalveolar carcinoma of the lung: report of 53 patients].
  • OBJECTIVE: To analyze the clinical feature and the value of chemotherapy for advanced stage bronchioloalveolar carcinoma (BAC) of the lung.
  • RESULTS: Of these 53 eligible patients in this series, 34 (64.2%) were women, 42 (79.2%) never smoked any cigarette, 29 (54.7%) originated from the right lung, and 12 patients (22.6%) showed bilateral multi-lobular or multi-central lesions or diffusive pulmonary involvement.
  • CONCLUSION: Advanced bronchioloalveolar carcinoma is likely to occur in woman, nonsmoker and the right lung, frequently with bilateral diffuse pulmonary involvement.
  • Compared with the historical data of lung adenocarcinoma of the same stage, bronchioloalveolar carcinoma has a longer overall survived.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760260.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


95. Freemantle SJ, Dmitrovsky E: Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention. Cancer Prev Res (Phila); 2010 Dec;3(12):1513-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention.
  • Lung cancer is the leading cause of cancer-related mortality in the United States and many other countries.
  • This fact underscores the need for clinically relevant models to increase our understanding of lung cancer biology and to help design and implement preventive and more effective therapeutic interventions for lung cancer.
  • New murine transgenic models of non-small cell lung cancer (NSCLC) have been engineered for this purpose.
  • In one such model, overexpression of the cell-cycle regulator cyclin E is targeted to type II alveolar lung cells; dysplasia, hyperplasia, and adenocarcinoma forming in this model have features recapitulating key features of carcinogenesis found in NSCLC patients.
  • Cell lines that expressed either a human wild-type or mutant (proteasome-degradation-resistant) form of cyclin E were derived from the transgenic mouse lung cancers.
  • These cell lines are transplantable into syngeneic host mice, which rapidly develop lung tumors and thus facilitate the rapid testing of agents targeting lung carcinogenesis.
  • This review discusses the general utility of murine carcinogen-induced and transgenic models of lung carcinogenesis and describes the optimization of cyclin E-overexpressing lung carcinogenesis models and their use in testing candidate agents for the prevention and therapy of lung cancer.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Cancer Res. 2000 Jan 15;60(2):242-4 [10667567.001]
  • [Cites] J Clin Invest. 2009 Oct;119(10):3000-10 [19759520.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] J Cell Biol. 2004 Jun 21;165(6):789-800 [15197178.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1396-403 [4040798.001]
  • [Cites] Cancer Res. 1992 May 1;52(9 Suppl):2702s-2706s [1314134.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1672-7 [8939849.001]
  • [Cites] Clin Cancer Res. 2010 Jan 1;16(1):109-20 [20028770.001]
  • [Cites] Nat Biotechnol. 2010 Jan;28(1):71-8 [20023657.001]
  • [Cites] Eur Respir J. 2010 Feb;35(2):426-43 [20123848.001]
  • [Cites] J Clin Invest. 2010 Apr;120(4):1298-309 [20237410.001]
  • [Cites] Adv Cancer Res. 2010;106:113-64 [20399958.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2470-6 [10344760.001]
  • [Cites] Nature. 1999 Sep 16;401(6750):297-300 [10499591.001]
  • [Cites] Genes Dev. 2005 Mar 15;19(6):643-64 [15769940.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):3974-86 [15930332.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10280-8 [16288016.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5947-52 [16585505.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2943-9 [16331279.001]
  • [Cites] Genes Dev. 2006 Jun 1;20(11):1496-510 [16705038.001]
  • [Cites] J Pathol. 2006 Aug;209(4):512-21 [16739112.001]
  • [Cites] Nature. 2006 Aug 24;442(7105):947-51 [16862117.001]
  • [Cites] Cancer Lett. 2006 Nov 28;244(1):53-60 [16446029.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):1046-55 [16909105.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4089-94 [17360482.001]
  • [Cites] Clin Transl Oncol. 2007 Apr;9(4):216-20 [17462973.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):645-58 [17687385.001]
  • [Cites] Trends Pharmacol Sci. 2008 Jan;29(1):16-21 [18054800.001]
  • [Cites] Nature. 2008 Apr 17;452(7189):896-9 [18368051.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):281-3 [18835029.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1177-83 [19228723.001]
  • [Cites] Nat Rev Cancer. 2009 Mar;9(3):153-66 [19238148.001]
  • [Cites] Methods Mol Biol. 2009;530:365-78 [19266338.001]
  • [Cites] Proc Am Thorac Soc. 2009 Apr 15;6(2):201-5 [19349489.001]
  • [Cites] Nat Protoc. 2009;4(7):1064-72 [19561589.001]
  • [Cites] Lung Cancer. 2009 Oct;66(1):64-74 [19200615.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1152-7 [11861397.001]
  • (PMID = 21149327.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA132166-02; United States / NCI NIH HHS / CA / R03-CA132166; United States / NCI NIH HHS / CA / CA132166-02; United States / NCI NIH HHS / CA / R01-CA087546; United States / NCI NIH HHS / CA / CA087546-08; United States / NCI NIH HHS / CA / R01 CA087546-10; United States / NCI NIH HHS / CA / R01 CA087546-02; United States / NCI NIH HHS / CA / CA087546-03; United States / NCI NIH HHS / CA / R01 CA111422; United States / NCI NIH HHS / CA / CA111422-01A1; United States / NCI NIH HHS / CA / R03 CA130102-02; United States / NCI NIH HHS / CA / R01 CA111422-05A1; United States / NCI NIH HHS / CA / CA087546-07; United States / NCI NIH HHS / CA / R01 CA111422-06; United States / NCI NIH HHS / CA / R01 CA087546-04; United States / NCI NIH HHS / CA / R01 CA111422-02; United States / NCI NIH HHS / CA / R03 CA130102; United States / NCI NIH HHS / CA / R01 CA087546-07; United States / NCI NIH HHS / CA / R01-CA111422; United States / NCI NIH HHS / CA / CA087546-10; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / CA132166-01; United States / NCI NIH HHS / CA / CA111422-06; United States / NCI NIH HHS / CA / CA111422-05A1; United States / NCI NIH HHS / CA / CA087546-04; United States / NCI NIH HHS / CA / R03-CA130102; United States / NCI NIH HHS / CA / CA087546-05; United States / NCI NIH HHS / CA / CA111422-02; United States / NCI NIH HHS / CA / R01 CA087546-08; United States / NCI NIH HHS / CA / CA087546-09; United States / NCI NIH HHS / CA / R01 CA087546-05; United States / NCI NIH HHS / CA / R01 CA087546; United States / NCI NIH HHS / CA / R01 CA111422-03; United States / NCI NIH HHS / CA / CA111422-04; United States / NCI NIH HHS / CA / R01 CA087546-01; United States / NCI NIH HHS / CA / R03 CA132166-01; United States / NCI NIH HHS / CA / R01 CA087546-06A1; United States / NCI NIH HHS / CA / CA087546-06A1; United States / NCI NIH HHS / CA / CA130102-02; United States / NCI NIH HHS / CA / CA087546-01; United States / NCI NIH HHS / CA / R01 CA087546-09; United States / NCI NIH HHS / CA / CA111422-03; United States / NCI NIH HHS / CA / CA130102-01; United States / NCI NIH HHS / CA / CA087546-02; United States / NCI NIH HHS / CA / R01 CA111422-01A1; United States / NCI NIH HHS / CA / R01 CA111422-04; United States / NCI NIH HHS / CA / R01 CA087546-03; United States / NCI NIH HHS / CA / R03 CA132166; United States / NCI NIH HHS / CA / R03 CA130102-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclin E
  • [Other-IDs] NLM/ NIHMS249483; NLM/ PMC3058281
  •  go-up   go-down


96. Moran CA: Pulmonary adenocarcinoma: the expanding spectrum of histologic variants. Arch Pathol Lab Med; 2006 Jul;130(7):958-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary adenocarcinoma: the expanding spectrum of histologic variants.
  • Pulmonary adenocarcinoma is one of the most common types of lung cancer.
  • In the majority of cases, this schema is sufficient to categorize these lung tumors.
  • Thus, although the terminology of adenocarcinoma is applied in such cases, the histopathologic features are different from those of the more conventional variants.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / chemistry. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / pathology. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Carcinoma, Endometrioid / pathology. Carcinoma, Non-Small-Cell Lung / chemistry. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / pathology. Carcinoma, Signet Ring Cell / chemistry. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / pathology. Humans. Male

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831050.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 33
  •  go-up   go-down


97. Lee HY, Lee KS, Han J, Kim BT, Cho YS, Shim YM, Kim J: Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons. Lung Cancer; 2009 Aug;65(2):170-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Mucinous / pathology. Lung Neoplasms / pathology. Positron-Emission Tomography. Solitary Pulmonary Nodule / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19111932.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


98. Pramesh CS, Mistry RC, Agarwal J: How should bronchioloalveolar carcinoma of the lung 3 centimeters or less be treated? Ann Thorac Surg; 2005 Nov;80(5):1978; author reply 1979
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How should bronchioloalveolar carcinoma of the lung 3 centimeters or less be treated?
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / surgery. Lung Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Thorac Surg. 2004 Nov;78(5):1728-33 [15511463.001]
  • (PMID = 16242510.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


99. Varlotto JM, Flickinger JC, Recht A, Nikolov MC, DeCamp MM: A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer: implications for adjuvant therapy. Cancer; 2008 Apr 1;112(7):1547-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer: implications for adjuvant therapy.
  • BACKGROUND: The objective of this study was to assess whether disease-specific survival (DSS) and overall survival (OS) differed among patients who had N1 and N2 bronchioloalveolar carcinoma (BAC) compared with patients who had non-BAC nonsmall cell lung cancer (NSCLC).
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / mortality. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2008 Sep 1;113(5):1107-8; author reply 1108-9 [18618507.001]
  • (PMID = 18260087.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Boukakis G, Patrinou-Georgoula M, Lekarakou M, Valavanis C, Guialis A: Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues. BMC Cancer; 2010;10:434
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues.
  • The altered expression pattern of hnRNP A2/B1 and/or splicing variant B1 alone in human lung cancer and their potential to serve as molecular markers for early diagnosis remain issues of intense investigation.
  • The main objective of the present study was to use paired tumour/non-tumour biopsies from patients with non-small cell lung cancer (NSCLC) to investigate the expression profiles of hnRNP A1, A2/B1 and A3 in conjunction with ASF/SF2.
  • METHODS: We combined western blotting of tissue homogenates with immunohistochemical examination of fixed tissue sections and quantification of mRNA expression levels in tumour versus adjacent normal-looking areas of the lung in the same patient.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / metabolism. Heterogeneous-Nuclear Ribonucleoprotein Group A-B / metabolism. Lung / metabolism. RNA, Messenger / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Aged. Blotting, Western. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Female. Humans. Immunoenzyme Techniques. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. RNA-Binding Proteins / genetics. RNA-Binding Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Serine-Arginine Splicing Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2000 Apr;16(4):763-7 [10717246.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4048-52 [10632338.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1896-902 [11280744.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2A):979-84 [11396191.001]
  • [Cites] Lung Cancer. 2001 Dec;34(3):341-50 [11714531.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):195-205 [11994740.001]
  • [Cites] Cancer Lett. 2002 Sep 26;183(2):215-20 [12065097.001]
  • [Cites] Lung Cancer. 2003 Apr;40(1):45-53 [12660006.001]
  • [Cites] J Pathol. 2003 May;200(1):88-94 [12692846.001]
  • [Cites] Lung Cancer. 2003 Aug;41(2):131-43 [12871776.001]
  • [Cites] Lung Cancer. 2003 Aug;41(2):179-86 [12871781.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1493-501 [14562022.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7679-88 [14633690.001]
  • [Cites] Mol Carcinog. 2004 Dec;41(4):187-96 [15390079.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(24):9788-92 [2557628.001]
  • [Cites] Annu Rev Biochem. 1993;62:289-321 [8352591.001]
  • [Cites] Science. 1994 Jul 29;265(5172):615-21 [8036511.001]
  • [Cites] Genomics. 1995 Jan 20;25(2):365-71 [7789969.001]
  • [Cites] Exp Cell Res. 1995 Nov;221(1):187-96 [7589244.001]
  • [Cites] J Biol Chem. 1996 May 3;271(18):10760-6 [8631886.001]
  • [Cites] RNA. 1998 Apr;4(4):430-44 [9630249.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1631-40 [9676837.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Oct;19(4):554-62 [9761751.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5818-24 [9865741.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2237-46 [9815620.001]
  • [Cites] Exp Cell Res. 1999 Feb 1;246(2):399-411 [9925756.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1720-30 [10022859.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1404-7 [10197602.001]
  • [Cites] Curr Opin Cell Biol. 1999 Jun;11(3):363-71 [10395553.001]
  • [Cites] Int J Oncol. 2005 Mar;26(3):635-40 [15703818.001]
  • [Cites] Genes Dev. 2005 Mar 15;19(6):643-64 [15769940.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):888-95 [15964549.001]
  • [Cites] J Cell Sci. 2005 Jul 15;118(Pt 14):3173-83 [16014382.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1765(2):85-100 [16378690.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):395-402 [17067748.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1638-42 [17363515.001]
  • [Cites] Cancer Genomics Proteomics. 2007 May-Jun;4(3):233-9 [17878526.001]
  • [Cites] Mol Carcinog. 2007 Nov;46(11):887-900 [17477362.001]
  • [Cites] FEBS Lett. 2008 Jun 18;582(14):1977-86 [18342629.001]
  • [Cites] Curr Med Chem. 2009;16(9):1047-61 [19275611.001]
  • [Cites] Anticancer Res. 2009 Apr;29(4):1373-82 [19414390.001]
  • [Cites] Am J Respir Cell Mol Biol. 2000 Nov;23(5):636-45 [11062142.001]
  • (PMID = 20716340.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HNRNPA3 protein, human; 0 / Heterogeneous-Nuclear Ribonucleoprotein Group A-B; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / hnRNP A1; 170974-22-8 / Serine-Arginine Splicing Factors
  • [Other-IDs] NLM/ PMC2933625
  •  go-up   go-down






Advertisement